<article article-type="review-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Adv Res</journal-id><journal-id journal-id-type="iso-abbrev">J Adv Res</journal-id><journal-id journal-id-type="pmc-domain-id">2546</journal-id><journal-id journal-id-type="pmc-domain">jare</journal-id><journal-title-group><journal-title>Journal of Advanced Research</journal-title></journal-title-group><issn pub-type="ppub">2090-1232</issn><issn pub-type="epub">2090-1224</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12793736</article-id><article-id pub-id-type="pmcid-ver">PMC12793736.1</article-id><article-id pub-id-type="pmcaid">12793736</article-id><article-id pub-id-type="pmcaiid">12793736</article-id><article-id pub-id-type="pmid">39681285</article-id><article-id pub-id-type="doi">10.1016/j.jare.2024.12.020</article-id><article-id pub-id-type="pii">S2090-1232(24)00598-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmaceutical Science</subject></subj-group></article-categories><title-group><article-title>Advances in statin adverse reactions and the potential mechanisms: A systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Zeng</surname><given-names initials="W">Weiwei</given-names></name><xref ref-type="aff" rid="af005">a</xref><xref ref-type="fn" rid="fn1">1</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Deng</surname><given-names initials="H">Huan</given-names></name><xref ref-type="aff" rid="af005">a</xref><xref ref-type="fn" rid="fn1">1</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Luo</surname><given-names initials="Y">Yuning</given-names></name><xref ref-type="aff" rid="af005">a</xref><xref ref-type="fn" rid="fn1">1</xref></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Zhong</surname><given-names initials="S">Shilong</given-names></name><xref ref-type="aff" rid="af010">b</xref></contrib><contrib contrib-type="author" id="au025"><name name-style="western"><surname>Huang</surname><given-names initials="M">Min</given-names></name><email>huangmin@mail.sysu.edu.cn</email><xref ref-type="aff" rid="af015">c</xref><xref ref-type="corresp" rid="cor1">⁎</xref></contrib><contrib contrib-type="author" id="au030"><name name-style="western"><surname>Tomlinson</surname><given-names initials="B">Brian</given-names></name><email>btomlinson@must.edu.mo</email><xref ref-type="aff" rid="af020">d</xref><xref ref-type="corresp" rid="cor1">⁎</xref></contrib><aff id="af005"><label>a</label>Department of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen 518112, Guangdong, China</aff><aff id="af010"><label>b</label>Department of Pharmacy, Guangdong Provincial People’s Hospital, Guangzhou, Guangdong, China</aff><aff id="af015"><label>c</label>Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China</aff><aff id="af020"><label>d</label>Faculty of Medicine, Macau University of Science and Technology, Taipa, Macau</aff></contrib-group><author-notes><corresp id="cor1"><label>⁎</label>Corresponding authors. <email>huangmin@mail.sysu.edu.cn</email><email>btomlinson@must.edu.mo</email></corresp><fn id="fn1"><label>1</label><p id="np005"><bold>These authors have contributed equally to this work and share first.</bold></p></fn></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2024</year></pub-date><volume>76</volume><issue-id pub-id-type="pmc-issue-id">504886</issue-id><fpage>781</fpage><lpage>797</lpage><history><date date-type="received"><day>6</day><month>4</month><year>2024</year></date><date date-type="rev-recd"><day>9</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-13 10:25:14.510"><day>13</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2024 Published by Elsevier B.V. on behalf of Cairo University.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder/><license><ali:license_ref content-type="ccbyncndlicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="main.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract abstract-type="graphical" id="ab005"><title>Graphical abstract</title><fig id="f0030" orientation="portrait" position="anchor"><graphic id="lk00065" orientation="portrait" position="float" xlink:href="ga1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></abstract><abstract abstract-type="author-highlights" id="ab010"><title>Highlights</title><p><list id="l0005" list-type="simple"><list-item id="o0005"><label>•</label><p id="p0005">The risk factors, pathogenesis, interventions for adverse reactions to statins et al are presented.</p></list-item><list-item id="o0010"><label>•</label><p id="p0010">SAMS of statins may be closely related to the SLCO1B1 gene variants, mitochondrial damage, regulation of AKT et al.</p></list-item><list-item id="o0015"><label>•</label><p id="p0015">Hepatotoxicity of statins may be more significantly correlated with the expression mitochondrial damage, and DNA levels.</p></list-item><list-item id="o0020"><label>•</label><p id="p0020">Statin-induced glycemic abnormalities may be associated with insulin sensitivity and genetic polymorphisms.</p></list-item><list-item id="o0025"><label>•</label><p id="p0025">The synthesis of cholesterol may induce insomnia, vertigo, and memory dysfunction et al after statins.</p></list-item></list></p></abstract><abstract id="ab015"><p><bold>Background:</bold> Elevated low-density lipoprotein (LDL) cholesterol is a major risk factor for cardiovascular disease. Statins are the cornerstone of preventing and treating cardiovascular disease and can reduce LDL cholesterol by more than 60%. Although statins have high tolerability and safety, as the number of users increases, their adverse reactions in the liver, kidneys, skeletal muscles, and their potential to induce diabetes have also received widespread attention.</p><p>Aim <bold>of review:</bold> How to maximize the lipid-lowering effect of statins, reduce the incidence of adverse reactions, promote the rational application of statins in the clinic, and improve the risk–benefit level, in order to benefit more cardiovascular patients and provide reference for the related basic research of statins.</p><p><bold>Key scientific concepts of review:</bold> This article provides a comprehensive review of the clinical manifestations of statin-related adverse reactions (associated myopathy, hepatotoxicity, nephrotoxicity, glycemic effects, central nervous system, hemorrhagic stroke, etc.), risk factors for triggering adverse reactions, statin interactions with other drugs (food), potential etiopathological mechanisms and common interventions in the clinic. Genetic diversity is strongly associated with statin adverse effects, and thus, in the future genetic testing may also be key to mitigating statin adverse effects.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Statins</kwd><kwd>adverse effects</kwd><kwd>mechanism</kwd><kwd>clinical interventions</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="k0030">HMG-CoA</term><def><p>3-hydroxy-3-methyl glutaryl coenzyme A</p></def></def-item><def-item><term id="k0040">CVD</term><def><p>Cardiovascular diseases</p></def></def-item><def-item><term id="k0050">LDL-C</term><def><p>Low density lipoprotein cholesterol</p></def></def-item><def-item><term id="k0060">HMGS</term><def><p>HMG-CoA synthase</p></def></def-item><def-item><term id="k0070">HMGR</term><def><p>HMG-CoA reductase</p></def></def-item><def-item><term id="k0080">MVA</term><def><p>Mevalonate</p></def></def-item><def-item><term id="k0090">MVK</term><def><p>Mevalonate kinase</p></def></def-item><def-item><term id="k0100">MVP</term><def><p>Mevalonate-5-phosphate</p></def></def-item><def-item><term id="k0110">PMK</term><def><p>Phoshomevalonate kinase</p></def></def-item><def-item><term id="k0120">MVPP</term><def><p>Mevalonate-5-prophosphate, MDD, Mevalonate-5-pyrophosphate decarboxylase</p></def></def-item><def-item><term id="k0130">IPP</term><def><p>Isoentenyl-5-pyrophosphate</p></def></def-item><def-item><term id="k0140">GPP</term><def><p>Geranyl-5-pyrophosphate</p></def></def-item><def-item><term id="k0150">FPP</term><def><p>Farnesyl-5-pyrophosphate</p></def></def-item><def-item><term id="k0160">GGPP</term><def><p>Geranylgeranyl-5-pyrophosphate</p></def></def-item><def-item><term id="k0170">SR</term><def><p>Sarcoplasmic Reticulum</p></def></def-item><def-item><term id="k0180">SAMS</term><def><p>Statins-associated muscle symptoms</p></def></def-item><def-item><term id="k0190">CK</term><def><p>Creatine Kinase</p></def></def-item><def-item><term id="k0200">CYP</term><def><p>cytochrome P450</p></def></def-item><def-item><term id="k0210">OATP1B1</term><def><p>Organic anion transporting polypeptide 1B1</p></def></def-item><def-item><term id="k0220">UGT</term><def><p>uridine diphosphate glucuronosyltransferase</p></def></def-item><def-item><term id="k0230">SLCO1B1</term><def><p>Solute carrier organic anion transporter family member 1B1</p></def></def-item><def-item><term id="k0240">SLCO1B3</term><def><p>Solute carrier organic anion transporter family member 1B3</p></def></def-item><def-item><term id="k0250">ABCB11</term><def><p>ATP binding cassette subfamily B member 11</p></def></def-item><def-item><term id="k0260">PBPK</term><def><p>Physiologically based pharmacokinetic</p></def></def-item><def-item><term id="k0270">OATP1B3</term><def><p>Organic anion transporting polypeptides 1B3</p></def></def-item><def-item><term id="k0280">ABCC2</term><def><p>ATP binding cassette subfamily C member 2</p></def></def-item><def-item><term id="k0290">SNP</term><def><p>Single nucleotide polymorphism</p></def></def-item><def-item><term id="k0300">GATM</term><def><p>Glycine amidino transferase</p></def></def-item><def-item><term id="k0310">CPT1</term><def><p>Carnitine palmityl transferase Ⅰ</p></def></def-item><def-item><term id="k0320">CPT2</term><def><p>Carnitine palmityl transferase Ⅱ</p></def></def-item><def-item><term id="k0330">ROS</term><def><p>Reactive oxygen species</p></def></def-item><def-item><term id="k0340">SMCI</term><def><p>Statin Myalgia Clinical Index</p></def></def-item><def-item><term id="k0350">SAMS-CI</term><def><p>Statin-Associated Muscle Symptom Clinical Index</p></def></def-item><def-item><term id="k0360">RCC</term><def><p>Renal cell carcinoma</p></def></def-item><def-item><term id="k0370">BCRP</term><def><p>Breast cancer resistance protein</p></def></def-item><def-item><term id="k0380">SV</term><def><p>Simvastatin</p></def></def-item><def-item><term id="k0390">ALT</term><def><p>Alanine Aminotransferas</p></def></def-item><def-item><term id="k0400">AST</term><def><p>Aspartate Aminotransferase</p></def></def-item><def-item><term id="k0410">ULN</term><def><p>Upper limit of normal</p></def></def-item><def-item><term id="k0420">TBIL</term><def><p>Total bilirubin</p></def></def-item><def-item><term id="k0430">NAFLD</term><def><p>Non-alcoholic fatty liver disease</p></def></def-item><def-item><term id="k0440">NODM</term><def><p>New-onset diabetes mellitus</p></def></def-item><def-item><term id="k0450">OR</term><def><p>Odds ratio</p></def></def-item><def-item><term id="k0460">HR</term><def><p>Hazard ratio</p></def></def-item><def-item><term id="k0470">OS</term><def><p>Overall survival</p></def></def-item><def-item><term id="k0480">PDAC</term><def><p>Pancreatic ductal adenocarcinoma</p></def></def-item></def-list></front><body><sec id="s0005"><title>Introduction</title><p id="p0030">Cardiovascular diseases (CVD) are the major cause of death throughout the world. Their prevalence is increasing each year bringing serious health and economic burdens to patients and more than 40 % of patients die of CVD in China <xref ref-type="bibr" rid="b0005">[1]</xref>. Lipid disorders (especially low-density lipoprotein cholesterol disorders) are the most clear risk factor for the development of cardiovascular disease, and statins are currently the first-line therapeutic agents for hypercholesterolemia and prevention of cardiovascular events. Clinical studies and <italic toggle="yes">meta</italic>-analysis have confirmed that statins could reduce cardiovascular events by about 20 % for every 1 mmol/L (38.7 mg/dL) reduction in low-density lipoprotein (LDL) cholesterol <xref ref-type="bibr" rid="b0010">[2]</xref>, <xref ref-type="bibr" rid="b0015">[3]</xref>. The powerful lipid-lowering effect of statins was achieved by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity, blocking intracellular cholesterol synthesis pathways, decreasing bile acid excretion, up-regulating the expression of the LDL receptor (LDLR), and lowering the level of circulating LDL cholesterol (<xref ref-type="fig" rid="f0005">Fig. 1</xref>) <xref ref-type="bibr" rid="b0020">[4]</xref>. In addition, statins have potent anti-inflammatory <xref ref-type="bibr" rid="b0025">[5]</xref>, plaque stabilizing <xref ref-type="bibr" rid="b0030">[6]</xref>, improved endothelial cell function <xref ref-type="bibr" rid="b0035">[7]</xref>, improved left ventricular function <xref ref-type="bibr" rid="b0040">[8]</xref> and neuroprotective and antithrombotic effects <xref ref-type="bibr" rid="b0045">[9]</xref>. This has laid the cornerstone of statins in the treatment of CVD. The adverse effects and possible mechanisms of the different statins are illustrated in <xref ref-type="table" rid="t0005">Table 1</xref>.<fig id="f0005" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Statins interfere with the synthesis of bioactive substances downstream of HMG-CoA.</p></caption><graphic id="lk00005" orientation="portrait" position="float" xlink:href="gr1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 1</label><caption><p>Adverse effects and possible mechanisms with statins.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Drug Name</th><th colspan="1" rowspan="1">Chemical structure</th><th colspan="1" rowspan="1">Adverse reaction</th><th colspan="1" rowspan="1">Incidence of disease</th><th colspan="1" rowspan="1">Pharmacological mechanism</th></tr></thead><tbody><tr><td colspan="1" rowspan="4">Atorvastatin</td><td colspan="1" rowspan="4"><inline-graphic id="lk00030" xlink:href="fx7.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/></td><td colspan="1" rowspan="1">SAMS <xref ref-type="bibr" rid="b0050">[10]</xref></td><td colspan="1" rowspan="1">5/10000 <xref ref-type="bibr" rid="b0055">[11]</xref></td><td colspan="1" rowspan="1"><italic toggle="yes">SLCO1B1</italic> gene diversity <xref ref-type="bibr" rid="b0060">[12]</xref>；<break/>Inhibition of the AKT pathway <xref ref-type="bibr" rid="b0065">[13]</xref>；<break/>Increase in Ca<sup>2+</sup> concentration <xref ref-type="bibr" rid="b0070">[14]</xref>；<break/>Inhibition of GTPases <xref ref-type="bibr" rid="b0075">[15]</xref>.<xref ref-type="bibr" rid="b0025">[5]</xref>, <xref ref-type="bibr" rid="b0030">[6]</xref></td></tr><tr><td colspan="1" rowspan="1">Statin-associated liver injury<xref ref-type="bibr" rid="b0080">[16]</xref></td><td colspan="1" rowspan="1">4/10000<xref ref-type="bibr" rid="b0085">[17]</xref></td><td colspan="1" rowspan="1">Induction of apoptosis in hepatocytes <xref ref-type="bibr" rid="b0090">[18]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Diabetes mellitus <xref ref-type="bibr" rid="b0095">[19]</xref></td><td colspan="1" rowspan="1">50/10000–100/10000 <xref ref-type="bibr" rid="b0055">[11]</xref></td><td colspan="1" rowspan="1">Inhibits insulin secretion <xref ref-type="bibr" rid="b0095">[19]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Hemorrhagic stroke <xref ref-type="bibr" rid="b0100">[20]</xref></td><td colspan="1" rowspan="1">5/10000–10/10000 <xref ref-type="bibr" rid="b0055">[11]</xref></td><td colspan="1" rowspan="1">Mechanisms not yet clear.</td></tr><tr><td colspan="1" rowspan="3">Rosuvastatin</td><td colspan="1" rowspan="3"><inline-graphic id="lk00035" xlink:href="fx8.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/></td><td colspan="1" rowspan="1">SAMS <xref ref-type="bibr" rid="b0050">[10]</xref></td><td colspan="1" rowspan="1">15.3/10000<xref ref-type="bibr" rid="b0105">[21]</xref></td><td colspan="1" rowspan="1">Inhibition of the AKT pathway <xref ref-type="bibr" rid="b0065">[13]</xref>；<break/>Increase in Ca<sup>2+</sup> concentration <xref ref-type="bibr" rid="b0070">[14]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Renal failure <xref ref-type="bibr" rid="b0110">[22]</xref></td><td colspan="1" rowspan="1">120/10000 <xref ref-type="bibr" rid="b0110">[22]</xref></td><td colspan="1" rowspan="1">Proteinuria <xref ref-type="bibr" rid="b0110">[22]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Diabetes mellitus <xref ref-type="bibr" rid="b0115">[23]</xref></td><td colspan="1" rowspan="1">340/10000 <xref ref-type="bibr" rid="b0115">[23]</xref></td><td colspan="1" rowspan="1">Mechanisms not yet clear.</td></tr><tr><td colspan="1" rowspan="1">Pravastatin</td><td colspan="1" rowspan="1"><inline-graphic id="lk00040" xlink:href="fx9.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/></td><td colspan="1" rowspan="1">SAMS <xref ref-type="bibr" rid="b0050">[10]</xref></td><td colspan="1" rowspan="1">2.5/10000 <xref ref-type="bibr" rid="b0105">[21]</xref></td><td colspan="1" rowspan="1">Increase in Ca<sup>2+</sup> concentration <xref ref-type="bibr" rid="b0070">[14]</xref>；<break/>Inhibition of GTPases <xref ref-type="bibr" rid="b0120">[24]</xref>.</td></tr><tr><td colspan="1" rowspan="2">Fluvastatin</td><td colspan="1" rowspan="2"><inline-graphic id="lk00045" xlink:href="fx10.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/></td><td colspan="1" rowspan="1">SAMS <xref ref-type="bibr" rid="b0050">[10]</xref></td><td colspan="1" rowspan="1">No relevant data available</td><td colspan="1" rowspan="1">Inhibition of GTPases <xref ref-type="bibr" rid="b0125">[25]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Statin-associated liver injury <xref ref-type="bibr" rid="b0090">[18]</xref></td><td colspan="1" rowspan="1">No relevant data available</td><td colspan="1" rowspan="1">Induction of apoptosis in hepatocytes <xref ref-type="bibr" rid="b0090">[18]</xref>.</td></tr><tr><td colspan="1" rowspan="3">Pitavastatin</td><td colspan="1" rowspan="3"><inline-graphic id="lk00050" xlink:href="fx11.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/></td><td colspan="1" rowspan="1">SAMS <xref ref-type="bibr" rid="b0130">[26]</xref></td><td colspan="1" rowspan="1">45/1000 (Blood creatine kinase:27/1000; myalgia:11/1000)<break/>7/1000 ∼ 19/1000 (Risk increasing with higher doses) <xref ref-type="bibr" rid="b0135">[27]</xref></td><td colspan="1" rowspan="1">Mechanisms not yet clear.</td></tr><tr><td colspan="1" rowspan="1">Statin-associated liver injury <xref ref-type="bibr" rid="b0130">[26]</xref></td><td colspan="1" rowspan="1">28/1000 (alanine aminotransferase:18/1000; aspartate aminotransferase: 15/1000; gamma-glutamyltransferase: 10/1000)</td><td colspan="1" rowspan="1">Mechanisms not yet clear.</td></tr><tr><td colspan="1" rowspan="1">NODM <xref ref-type="bibr" rid="b0140">[28]</xref>, <xref ref-type="bibr" rid="b0145">[29]</xref></td><td colspan="1" rowspan="1">Does not increase the risk of NODM（the risk is the same in comparison to placebo in most available studies）</td><td colspan="1" rowspan="1">Improve carbohydrate disturbances, glucose levels, Hb1AC and HOMA-IR.</td></tr><tr><td colspan="1" rowspan="3">Lovastatin</td><td colspan="1" rowspan="3"><inline-graphic id="lk00055" xlink:href="fx12.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/></td><td colspan="1" rowspan="1">SAMS <xref ref-type="bibr" rid="b0050">[10]</xref></td><td colspan="1" rowspan="1">10/10000 <xref ref-type="bibr" rid="b0105">[21]</xref></td><td colspan="1" rowspan="1"><italic toggle="yes">SLCO1B1</italic> gene diversity <xref ref-type="bibr" rid="b0150">[30]</xref>；<break/><italic toggle="yes">GATM</italic> gene diversity <xref ref-type="bibr" rid="b0155">[31]</xref>.</td></tr><tr><td colspan="1" rowspan="1"><xref ref-type="bibr" rid="b0160">[32]</xref></td><td colspan="1" rowspan="1">6.2/10000 <xref ref-type="bibr" rid="b0165">[33]</xref></td><td colspan="1" rowspan="1"><italic toggle="yes">SLCO1B1</italic> gene diversity <xref ref-type="bibr" rid="b0170">[34]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Cognitive impairment <xref ref-type="bibr" rid="b0175">[35]</xref></td><td colspan="1" rowspan="1">No relevant data available</td><td colspan="1" rowspan="1">The drug enters the center and lowers cholesterol levels, leading to reduced nervous system conduction and mitochondrial function <xref ref-type="bibr" rid="b0180">[36]</xref>.</td></tr><tr><td colspan="1" rowspan="5">Simvastatin</td><td colspan="1" rowspan="5"><inline-graphic id="lk00060" xlink:href="fx13.gif" xmlns:xlink="http://www.w3.org/1999/xlink"/></td><td colspan="1" rowspan="1">SAMS <xref ref-type="bibr" rid="b0050">[10]</xref></td><td colspan="1" rowspan="1">60/10000 <xref ref-type="bibr" rid="b0055">[11]</xref>, <xref ref-type="bibr" rid="b0105">[21]</xref></td><td colspan="1" rowspan="1">Inhibition of the AKT pathway <xref ref-type="bibr" rid="b0065">[13]</xref>；Increase in Ca<sup>2+</sup> concentration <xref ref-type="bibr" rid="b0070">[14]</xref>；Inhibition of GTPases <xref ref-type="bibr" rid="b0185">[37]</xref>.{L, 2021 #9;B, 2016 #10}</td></tr><tr><td colspan="1" rowspan="1">Statin-associated liver injury <xref ref-type="bibr" rid="b0080">[16]</xref></td><td colspan="1" rowspan="1">6/10000 <xref ref-type="bibr" rid="b0085">[17]</xref></td><td colspan="1" rowspan="1"><italic toggle="yes">SLCO1B1</italic> gene diversity <xref ref-type="bibr" rid="b0190">[38]</xref>；<break/>Inhibition of mitochondrial function <xref ref-type="bibr" rid="b0195">[39]</xref>；<break/>Inhibition of Coenzyme Q10 <xref ref-type="bibr" rid="b0200">[40]</xref>；<break/>Induction of apoptosis in hepatocytes <xref ref-type="bibr" rid="b0205">[41]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Diabetes mellitus <xref ref-type="bibr" rid="b0095">[19]</xref></td><td colspan="1" rowspan="1">10/10000–20/10000 <xref ref-type="bibr" rid="b0055">[11]</xref></td><td colspan="1" rowspan="1">Inhibits insulin secretion <xref ref-type="bibr" rid="b0095">[19]</xref>；<break/>Inhibition of L-type Ca<sup>2+</sup> channel function in pancreatic β-cells <xref ref-type="bibr" rid="b0210">[42]</xref>；<break/>Reduces insulin sensitivity <xref ref-type="bibr" rid="b0215">[43]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Cognitive impairment <xref ref-type="bibr" rid="b0220">[44]</xref></td><td colspan="1" rowspan="1">No relevant data available</td><td colspan="1" rowspan="1">The drug enters the center and lowers cholesterol levels, leading to reduced nervous system conduction and mitochondrial function <xref ref-type="bibr" rid="b0225">[45]</xref>.</td></tr><tr><td colspan="1" rowspan="1">Hemorrhagic stroke <xref ref-type="bibr" rid="b0100">[20]</xref></td><td colspan="1" rowspan="1">No relevant data available</td><td colspan="1" rowspan="1">Mechanisms not yet clear.</td></tr></tbody></table></table-wrap></p><p id="p0035">Large-scale intervention studies and <italic toggle="yes">meta</italic>-analyses have confirmed the beneficial effects of statins in preventing cardiovascular events <xref ref-type="bibr" rid="b0230">[46]</xref>, <xref ref-type="bibr" rid="b0235">[47]</xref>. Although statins are generally well tolerated, studies have reported that 5–30 % of patients are intolerant to statins <xref ref-type="bibr" rid="b0240">[48]</xref>, <xref ref-type="bibr" rid="b0245">[49]</xref>, which can lead to reduced compliance and persistence with statin therapy, as well as an increased risk of adverse cardiovascular outcomes. Statin intolerance and non-adherence to statin therapy remain major barriers to the primary and secondary prevention of ASCVD <xref ref-type="bibr" rid="b0250">[50]</xref>, <xref ref-type="bibr" rid="b0255">[51]</xref>. There are numerous reasons for discontinuing statin drugs, such as statin-induced liver and kidney dysfunction, statin-related muscle symptoms (SAMS), new-onset diabetes, and cognitive impairment. Research has shown an increased risk of new-onset diabetes <xref ref-type="bibr" rid="b0260">[52]</xref> and elevated liver transaminases associated with the use of statin drugs <xref ref-type="bibr" rid="b0265">[53]</xref>, with the effects on muscle pain, muscle symptoms, and cognitive impairment still being debated. SAMS is the most common adverse reaction of statins, and it is the main reason for statin intolerance leading to discontinuation. Observational studies have reported SAMS in 10–29 % of patients, while in RCTs, the difference in muscle symptoms between the placebo group and the control group is minimal <xref ref-type="bibr" rid="b0240">[48]</xref>. Therefore, some studies speculate that SAMS may be the result of a “nocebo effect,” but there is controversy. A subgroup analysis of a <italic toggle="yes">meta</italic>-analysis incorporating 62 randomized controlled trials with a total of 102,456 adult patients without a history of ASCVD showed that, apart from atorvastatin which exhibited a significant dose–response relationship with liver function abnormalities, other statins had a lower risk of adverse events. However, there were slight differences in the impact of different types of statins on adverse events <xref ref-type="bibr" rid="b0270">[54]</xref>. <xref ref-type="table" rid="t0005">Table 1</xref> summarizes the correlation between different types of statins and adverse events. While statin therapy is generally safe, the side effects of statins should not be overlooked, as safety concerns are one of the most important factors leading to poor patient adherence to statin therapy.</p><p id="p0040">How to maximize the lipid-lowering effects of statins and reduce the adverse effects is a key issue in the clinical application of statins. Therefore, this review focuses on the review of the common adverse effects of statins in clinical practice, such as the associated myopathy, nephrotoxicity, hepatotoxicity, blood glucose abnormality, central nervous system effects, hemorrhagic stroke, etc., as well as the potential pathogenesis of these adverse effects and the intervention measures. This review provides some insights into preventing the adverse effects of statins, standardizing their clinical use, and improving the safety of the medications.</p></sec><sec id="s0010"><title>SAMS</title><sec id="s0015"><title>Background</title><p id="p0045">Statin-associated muscle symptoms (SAMS) are the most common side effect of statins, the real-world clinical statistics have found that the actual incidence of this condition can reach 10–29 %, and severe SAMS is the most common reason for statin discontinuation <xref ref-type="bibr" rid="b0100">[20]</xref>. The main sites of SAMS are the thighs, calves, and hip flexor muscles, and the symptoms are usually symmetrical <xref ref-type="bibr" rid="b0275">[55]</xref>. The symptoms are characterized by myalgia, myositis, and the most severe form, rhabdomyolysis, which leads to muscle pain, release of myoglobin and acute renal failure, which may progress to multi-organ failure. SAMS is marked by significant muscle damage as well as elevated serum creatine kinase (CK). The current study suggests that although the prevalence of any SAMS was relatively high, the prevalence of severe myopathy with creatine kinase (CK) ≥ 10 times normal and of rhabdomyolysis was low, at 1/1000 and 1/10,000, respectively <xref ref-type="bibr" rid="b0280">[56]</xref>. In addition, it was found that certain conditions such as the elderly (&gt;60 years of age), diabetic patients, hypothyroid patients, multisystem diseases, vitamin D deficiency, excessive physical activity, alcohol consumption, strenuous exercise, and major surgery, increased the risk of SAMS in a dose-dependent manner with respect to statin concentrations <xref ref-type="bibr" rid="b0275">[55]</xref>, <xref ref-type="bibr" rid="b0285">[57]</xref>.</p></sec><sec id="s0020"><title>Drug interactions</title><p id="p0050">The lipophilicity of statins has been considered to be associated with the risk of developing SAMS due to the ability of lipophilic statins to cross cell membranes and cause muscle damage <xref ref-type="bibr" rid="b0285">[57]</xref>. However, in a survey of 7924 French patients for muscle risk prediction under observational conditions, it was found that the incidence of SAMS with various statins was ranked as simvastatin (18.2 %), atorvastatin (14.9 %), pravastatin (10.9 %), and fluvastatin (5.1 %), which suggested that the incidence of SAMS with lipophilic statins was not necessarily higher than that with hydrophilic statins as pravastatin is hydrophilic and had a greater incidence than that of fluvastatin <xref ref-type="bibr" rid="b0290">[58]</xref>. The metabolism of some statins is mainly by the cytochrome P450 (CYP) enzymes. Another drug that inhibits the same metabolic pathway, the CYP enzymes such as CYP3A4 and CYP2C9 do not metabolize the statin to the same extent and higher plasma levels will occur with increased risk of muscle toxicity. For example, ranolazine, amiodarone, azole antifungals, and some immunosuppressants inhibit CYP3A4 metabolism and increase the risk of adverse effects when combined with statins <xref ref-type="bibr" rid="b0295">[59]</xref>, <xref ref-type="bibr" rid="b0300">[60]</xref>, <xref ref-type="bibr" rid="b0305">[61]</xref>. The interactions between statins and other drugs are shown in <xref ref-type="table" rid="t0010">Table 2</xref>.<table-wrap id="t0010" orientation="portrait" position="float"><label>Table 2</label><caption><p>Interactions between statins and other drugs <xref ref-type="bibr" rid="b0340">[68]</xref>, <xref ref-type="bibr" rid="b0345">[69]</xref>, <xref ref-type="bibr" rid="b0350">[70]</xref>, <xref ref-type="bibr" rid="b0355">[71]</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Drugs</th><th colspan="1" rowspan="1">Drug category</th><th colspan="1" rowspan="1">Affected statins</th><th colspan="1" rowspan="1">Potential mechanisms of drug-drug interaction</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Ketoconazole, itraconazole, fluconazole, voriconazole</td><td colspan="1" rowspan="1">Azole antifungals</td><td colspan="1" rowspan="1">Atorvastatin, fluvastatin, Pivastatin, Lovastatin, simvastatin, Rosuvastatin</td><td colspan="1" rowspan="1">Inhibited CYP3A4 and CYP2C9 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Ranolazine</td><td colspan="1" rowspan="1">Antianginal drug</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Amiodarone</td><td colspan="1" rowspan="1">Antiarrhythmic drug</td><td colspan="1" rowspan="1">Atorvastatin, fluvastatin, Pivastatin, Lovastatin, simvastatin, Rosuvastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 and CYP2C9 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Verapamil, Diltiazem</td><td colspan="1" rowspan="1">Calcium antagonists</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Clarithromycin, erythromycin, roxithromycin</td><td colspan="1" rowspan="1">Macrolides</td><td colspan="1" rowspan="1">All statins.</td><td colspan="1" rowspan="1">Decreased transport function of OATP1B1.</td></tr><tr><td colspan="1" rowspan="1">Cyclosporine</td><td colspan="1" rowspan="1">Immunosuppressant</td><td colspan="1" rowspan="1">All statins</td><td colspan="1" rowspan="1">Inhibited CYP3A4 metabolism and UTG activity. Decreased transport function of OATP1B1.</td></tr><tr><td colspan="1" rowspan="1">Tacrolimus</td><td colspan="1" rowspan="1">Immunosuppressant</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism. inhibit OATP1B1 and UGT</td></tr><tr><td colspan="1" rowspan="1">Amprenavir, atazanavir, darunavir, indinavir, lopinavir,</td><td colspan="1" rowspan="1">HIV medications</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Boceprevir, telaprevir.</td><td colspan="1" rowspan="1">Hepatitis C drugs</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Alprazolam, midazolam</td><td colspan="1" rowspan="1">Benzodiazepines</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Cotrimoxazole, tigecycline</td><td colspan="1" rowspan="1">Antibacterial agents</td><td colspan="1" rowspan="1">Fluvastatin, rosuvastatin, pivastatin</td><td colspan="1" rowspan="1">Inhibit CYP2C9 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Gemfibrozil</td><td colspan="1" rowspan="1">Lipid-regulating drug</td><td colspan="1" rowspan="1">All statins.</td><td colspan="1" rowspan="1">Inhibited UTG activity. Decreased transport function of OATP1B1.</td></tr><tr><td colspan="1" rowspan="1">Warfarin, ticagrelor</td><td colspan="1" rowspan="1">Anticoagulant drug</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Imatinib, lapatinib</td><td colspan="1" rowspan="1">Antineoplastic drugs</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr><tr><td colspan="1" rowspan="1">Insulin</td><td colspan="1" rowspan="1">Antidiabetics</td><td colspan="1" rowspan="1">All statins.</td><td colspan="1" rowspan="1">Induce abnormal insulin signalling and inhibits pancreatic β-cell secretion.</td></tr><tr><td colspan="1" rowspan="1">Grapefruit</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">Atorvastatin, simvastatin, Lovastatin</td><td colspan="1" rowspan="1">Inhibit CYP3A4 metabolism.</td></tr></tbody></table></table-wrap></p><p id="p0055">In addition, statins could interact with certain foods and herbal supplements <xref ref-type="bibr" rid="b0310">[62]</xref> thereby exacerbating the risk of statin-induced myopathy. For example, grapefruit used with lovastatin or simvastatin, resulted in increased blood levels of these statins with an increased risk of myopathy. Because the pharmacokinetic properties of lovastatin and simvastatin were similar, both are metabolized by CYP3A4, some studies have demonstrated that fruit juices such as lemon and grapefruit inhibit CYP3A4 and the organic anion transporting polypeptide 1B1 (OATP1B1), so the combination of these two drugs with certain fruit juices will lead to an increased risk of statin adverse effects <xref ref-type="bibr" rid="b0315">[63]</xref>. Lilja et al investigated the effect of grapefruit juice on the pharmacokinetics of simvastatin after consumption at different time intervals. It was found that concomitant administration of grapefruit juice and simvastatin resulted in a 13.5-fold increase in blood levels, whereas simvastatin blood levels were virtually unaffected when simvastatin was administered 3 days after grapefruit juice consumption <xref ref-type="bibr" rid="b0320">[64]</xref>. Further studies have demonstrated that the inhibitory effects of citrus juices on CYP3A4 and OATP1B1 are generally attributed to a class of phytochemicals known as flavonoids. In vitro experiments have also demonstrated that some flavonoid compounds inhibit CYP3A4 and OATP1B1 <xref ref-type="bibr" rid="b0325">[65]</xref>. In a study of the effect of grapefruit juice dosage on atorvastatin metabolism, it was found that long-term consumption of 300 mL of grapefruit juice did not lead to an increased risk of clinical side effects in patients, although it did increase atorvastatin blood levels by a small margin <xref ref-type="bibr" rid="b0330">[66]</xref>. It was worth noting that fluvastatin, pravastatin and rosuvastatin are not metabolized by CYP3A4, so these statins are not affected by fruit juices such as lemon and grapefruit, and if the patient wishes to consume such juices, they could consider replacing simvastatin or lovastatin with one of these alternatives <xref ref-type="bibr" rid="b0335">[67]</xref>.</p></sec><sec id="s0025"><title>Mechanism of adverse effects</title><p id="p0060">Researchers have conducted numerous studies on SAMS during statin therapy. It was found that the myotoxicity of statins may be closely related to gene polymorphisms, mitochondrial function, the PI3K/AKT pathway, Ca<sup>2+</sup> concentration, and regulation of GTPases. The possible mechanisms of statin-associated muscle injury are shown in <xref ref-type="fig" rid="f0010">Fig. 2</xref>.<fig id="f0010" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>The mechanism of statin-associated muscle injury.</p></caption><graphic id="lk00010" orientation="portrait" position="float" xlink:href="gr2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><sec id="s0030"><title>Genetic polymorphisms</title><p id="p0065">Multiple genome-wide association studies have indicated that the missense variant Asp247 in the leukocyte immunoglobulin-like receptor subfamily B member 5 gene (LILRSB5) is associated with CK levels, and the variant may cause susceptibility of statins to muscle-related symptoms with statins <xref ref-type="bibr" rid="b0360">[72]</xref>, <xref ref-type="bibr" rid="b0365">[73]</xref>. The later GoDARTS study further demonstrated a consistent association between the LILRB5 Asp247 genotype and the SI phenotype. Individuals carrying the LILRB5 Asp247 pure genotype may be statin intolerant and have increased CK levels after treatment, thereby enhancing the susceptibility to SAMS <xref ref-type="bibr" rid="b0370">[74]</xref>.</p><p id="p0070">OATP1B1 is one of the important members of the organic anion transporting polypeptide family, that is involved in transporting a variety of endogenous substances and drugs. It is encoded by the <italic toggle="yes">SLCO1B1</italic> gene, and it has been confirmed that OATP1B1 transports endogenous substances and many drugs including statins, hypoglycemic drugs, antihypertensive drugs, antiviral drugs, antibiotics and so on <xref ref-type="bibr" rid="b0375">[75]</xref>, <xref ref-type="bibr" rid="b0380">[76]</xref>. This provides a theoretical basis for the relationship between polymorphisms in the <italic toggle="yes">SLCO1B1</italic> gene and the occurrence of SAMS. Studies have found a strong association between <italic toggle="yes">SLCO1B1</italic> variants and particularly the c.521 T &gt; C variant allele (rs4149056) and statin-induced myotoxicity. Homozygous carriers of the C allele had a significantly increased risk of simvastatin- and lovastatin-induced myopathy and rhabdomyolysis <xref ref-type="bibr" rid="b0160">[32]</xref>, <xref ref-type="bibr" rid="b0385">[77]</xref>, <xref ref-type="bibr" rid="b0390">[78]</xref>. In addition to <italic toggle="yes">SLCO1B1</italic>, other transporters appear to have some association with SAMS risk, for example, Dagli-Hernandez et al. found in a case study of a delayed response to rosuvastatin that, in addition to a variant in the <italic toggle="yes">SLCO1B1</italic> gene, this patient also had low activity variants in <italic toggle="yes">SLCO1B3</italic> and <italic toggle="yes">ABCB11</italic>
<xref ref-type="bibr" rid="b0395">[79]</xref>.</p><p id="p0075">Wang et al. used a physiologically based pharmacokinetic (PBPK) model to predict that rifampicin and cyclosporine could increase the plasma exposure of rosuvastatin by inhibiting OATP1B1 and OATP1B3 and thereby predict drug-drug interactions <xref ref-type="bibr" rid="b0400">[80]</xref>. Woo et al. found that genetic variants in <italic toggle="yes">SLCO1B3</italic> and <italic toggle="yes">ABCC2</italic> in addition to <italic toggle="yes">SLCO1B1</italic> also affected the pharmacokinetic parameters of atorvastatin <xref ref-type="bibr" rid="b0060">[12]</xref>. In addition, single nucleotide polymorphisms (SNPs) in th<italic toggle="yes">e ABCB1</italic>, <italic toggle="yes">ABCG2</italic>, and <italic toggle="yes">ABCC2</italic> genes have been reported to have some association with the risk of SAMS, but none of them have been confirmed by consistent findings.<xref ref-type="bibr" rid="b0405">[81]</xref>. In addition to transporter-related genes, the activity of CYP450 enzymes plays a significant role in statin toxicity, most notably including CYP3A4/5 and CYP2C9. For example, CYP2C9 encodes a phase I drug metabolizing enzyme responsible for the oxidation of certain statins. Genetic variation in these genes could alter systemic exposure to some statins, thereby increasing the risk of developing SAMS <xref ref-type="bibr" rid="b0050">[10]</xref>.</p><p id="p0080">In 2013, Mangravite et al. were the first to suggest that the glycine amidinotransferase (GATM) gene may be associated with the incidence of SAMS and further studies found that the rs9806699 locus in the GATM gene was correlated with a reduced risk of SAMS <xref ref-type="bibr" rid="b0410">[82]</xref>. Subsequently, some other studies have also reached similar conclusions. Liu et al. found that the rs9806699 locus of the GATM gene, although not correlated with the prevalence of severe SAMS, may reduce the prevalence of mild SAMS <xref ref-type="bibr" rid="b0415">[83]</xref>. Bai et al. also showed that the rs9806699 locus, while not affecting the plasma exposure to rosuvastatin, did show a weak correlation with the risk of developing SAMS <xref ref-type="bibr" rid="b0155">[31]</xref>.Unfortunately, however, the correlation between the GATM gene and SAMS has not been confirmed by several other studies <xref ref-type="bibr" rid="b0420">[84]</xref>,. Case-control analyses found no correlation between GATM variants and SAMS risk. Thus, the association between the GATM gene variant and the incidence of SAMS needs to be explored in greater depth.</p></sec><sec id="s0035"><title>Mitochondrial function</title><p id="p0085">The mitochondrial electron transport chain, as an important component of mitochondrial oxidative phosphorylation (OXPHOS), has the most important physiological function of cellular ATP and reactive oxygen species generation, which directly affects the level of cellular energy metabolism. Among the components, key proteins such as mitochondrial complexes I, II, III, IV and coenzyme Q10 play an important role in this process <xref ref-type="bibr" rid="b0425">[85]</xref>, <xref ref-type="bibr" rid="b0430">[86]</xref>. The specific mechanism of action is shown in <xref ref-type="fig" rid="f0015">Fig. 3</xref>.<fig id="f0015" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Mitochondrial electron transport chain and ATP synthesis.</p></caption><graphic id="lk00015" orientation="portrait" position="float" xlink:href="gr3.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0090">Among the statins, atorvastatin, fluvastatin, and cerivastatin inhibit mitochondrial complexes I, III, and IV <xref ref-type="bibr" rid="b0435">[87]</xref>.In addition, simvastatin reduces mitochondrial DNA (mtDNA) levels, but atorvastatin does not significantly affect mtDNA levels, suggesting that the lipophilic nature of statins may cause mitochondrial damage <xref ref-type="bibr" rid="b0440">[88]</xref>, <xref ref-type="bibr" rid="b0445">[89]</xref>. Carnitine palmitoyltransferase CPT1 and CPT2 were both crucial proteins for mitochondrial long-chain fatty acid oxidation, and CPT2-deficient patients may be more likely to develop SAMS <xref ref-type="bibr" rid="b0450">[90]</xref>. In vitro studies have shown that statins inhibit CPT2 expression, which in turn may lead to rhabdomyolysis. Based on this, statins should be avoided in combination with drugs such as ipratropium, indololol, clozapine, and others that down-regulate CPT2, to reduce the risk of SAMS in patients <xref ref-type="bibr" rid="b0455">[91]</xref>. Inhibition of HMG-CoA reductase by statins leads to decreased levels of intermediates in several biological pathways, including polyhydroxycholesterol, and coenzyme Q10, a cofactor in the mitochondrial respiratory chain, which play important roles in energy metabolism and stabilizing muscle cell membranes <xref ref-type="bibr" rid="b0460">[92]</xref>, <xref ref-type="bibr" rid="b0465">[93]</xref>. Mitochondrial dysfunction was theorized to be associated with decreased levels of coenzyme Q10. Coenzyme Q10 is a downstream product of the HMG-CoA pathway and plays an important role in electron transfer in the mitochondrial respiratory chain. Decreased levels of coenzyme Q10 damage mitochondria in skeletal muscle, releasing free radicals and increasing the free radical load in skeletal muscle, which resulted in decreasing cellular antioxidant defenses and ultimately myopathy and oxidative damage in skeletal muscle <xref ref-type="bibr" rid="b0470">[94]</xref>, <xref ref-type="bibr" rid="b0475">[95]</xref>. The rs6535454A &gt; G and rs4693075 G &gt; A/C/T variants of the coenzyme Q2 (COQ2) gene, an important synthesizing gene for coenzyme Q10, correlate with increased risk of SAMS <xref ref-type="bibr" rid="b0405">[81]</xref>.</p><p id="p0095">PPAR-γ coactivator-1 (PGC-1), as a nuclear receptor regulator, plays an important role in cellular energy metabolism, and recent studies have shown that PGC-1 may play a vital physiological function in diseases such as heart failure and diabetes mellitus, and some of the results of the studies have shown that it has a certain role in rhabdomyolysis and liver injury <xref ref-type="bibr" rid="b0480">[96]</xref>. Panajatovic et al. demonstrated that PGC-1α had the ability to attenuate the myotoxicity of simvastatin by comparing the extent of myotoxicity of simvastatin in wild-type, PGC-1α knockout, and PGC-1α overexpressing mice <xref ref-type="bibr" rid="b0485">[97]</xref>. Vaughan et al. suggested that PGC-1 acted as an activator of the protein kinase B (AKT) pathway. The decrease in its expression level may be related to the inhibitory effect of AKT phosphorylation by simvastatin, which was mainly due to the ability of simvastatin to reduce the mRNA level of PGC-1α in cells <xref ref-type="bibr" rid="b0490">[98]</xref>. Singh et al. selectively knocked out the PGC-1β gene in mouse skeletal muscle and administered oral atorvastatin to the knockout and wild-type mice. They showed that after PGC-1β gene knockout, atorvastatin resulted in increased mitochondrial dysfunction, increased levels of ROS, and increased levels of apoptosis in myocytes of mice <xref ref-type="bibr" rid="b0495">[99]</xref>. Thes studies showed that PGC-1α and PGC-1β play an essential role in atorvastatin-induced muscle damage. The expression of PGC-1 in human muscle tissue decreases with age, which may explain the more severe muscle damage response in older patients treated with statins. This result was also consistent with the clinical phenomenon that older patients are at greater risk of developing SAMS <xref ref-type="bibr" rid="b0500">[100]</xref>.</p></sec><sec id="s0040"><title>PI3K/AKT pathway</title><p id="p0100">In recent years, it has been found that the myotoxicity of statins may be related to the inhibition of AKT phosphorylation and its related pathways. AKT is a key enzyme in the PI3K pathway. Reduced levels of AKT protein and decreased protein activity can have a significant impact on mitochondrial function, immune function, and endocrine regulation <xref ref-type="bibr" rid="b0505">[101]</xref>. Bonifacio et al. found that simvastatin and atorvastatin at 10 μM caused C2C12 myotubular cell injury and inhibited AKT phosphorylation, Rosuvastatin at 50 μM similarly exhibited C2C12 cytotoxicity and inhibition of AKT phosphorylation. It also inhibited C2C12 myotubular cell protein synthesis by further inhibiting phosphorylation of S6K and 4EBP1 through inhibition of the AKT/mTOR pathway. It also inhibited the phosphorylation of FoxO3a, which in turn upregulated the expression of MuRF1 and Atrogin1/MAFbx, leading to the atrophy of C2C12 myotubular cells <xref ref-type="bibr" rid="b0065">[13]</xref>. In addition, Bonifacio et al. found that simvastatin not only inhibited the phosphorylation of AKT, but also suppressed the stimulatory effect of insulin-like growth factor (IGF-1) on AKT phosphorylation. Thus, the protective effect of IGF-1 on muscle atrophy was inhibited. Simultaneous administration of simvastatin and IGF-1 on C2C12 cells demonstrated that IGF-1 partially alleviated simvastatin-induced myocyte damage <xref ref-type="bibr" rid="b0510">[102]</xref>.</p></sec><sec id="s0045"><title>Increased concentration of Ca<sup>2+</sup> in myocytes</title><p id="p0105">Statins decrease the ability of the stabilizing protein FK506 binding protein (FKBP12) in skeletal muscle to bind to sarcoplasmic reticulum Ca<sup>2+</sup> channels and RyR1. This increases the release of Ca<sup>2+</sup> from the sarcoplasmic reticulum, causing an imbalance in Ca<sup>2+</sup> levels in skeletal muscle cells, which in turn activated apoptotic signaling pathways and increases reactive nitrogen species/reactive oxygen species levels <xref ref-type="bibr" rid="b0070">[14]</xref>. Camerino et al. showed that statins may act by modulating protein kinase C (PKC) activity. This phosphorylates the ClC-1 chloride channel, which in turn shut down the channel, and even directly reduced the expression level of the ClC-1 chloride channel. With the reduction and closure of the ClC-1 chloride channel, rat skeletal muscle cells become quiescent, sarcoplasmic chloride conductance decreases, and intracellular resting Ca<sup>2+</sup> levels increase. This in turn caused damage to myocyte metabolism and muscle atrophy <xref ref-type="bibr" rid="b0515">[103]</xref>.</p></sec><sec id="s0050"><title>Inhibiting GTPase activity</title><p id="p0110">In addition, statins inhibit the synthesis of geranylgeranyl pyrophosphate (GGPP), a downstream product of the HMG-CoA pathway, reducing activation of GTPases such as RhoA and Rab. Cell membrane anchoring requires prenylation, and RhoA and Rab play crucial roles in cell survival, where RhoA enables actin to form stress fibers and Rab plays an important role in vesicle trafficking. Simvastatin and atorvastatin inhibit isoprenylation of the GTPase RAP reducing muscle cell viability <xref ref-type="bibr" rid="b0185">[37]</xref>, <xref ref-type="bibr" rid="b0520">[104]</xref>. Fluvastatin and pravastatin inhibit Rab activity, leading to morphological changes in myocyte organelles, including mitochondria, which ultimately leads to cell death <xref ref-type="bibr" rid="b0125">[25]</xref>, <xref ref-type="bibr" rid="b0525">[105]</xref>. In addition to this, simvastatin promotes translocation of Rac1 to the cell nucleus. and inhibits the sugar uptake function of muscle cells by reducing the protein binding of Rac1 to GTP <xref ref-type="bibr" rid="b0530">[106]</xref>.</p></sec></sec><sec id="s0055"><title>Intervention</title><p id="p0115">In clinical practice, due to the “nocebo effect” of statins, some patients present with myalgic symptoms that are not necessarily related to statins, so how to correctly and effectively determine if patients really have SAMS was a prerequisite for intervention <xref ref-type="bibr" rid="b0535">[107]</xref>. Some research evidence suggested that the occurrence of SAMS may be related to the nocebo/drucebo effect, which refers to the fact that the administration of an inert substance such as a placebo can also induce adverse effects, similar to the placebo effect <xref ref-type="bibr" rid="b0540">[108]</xref>. It should not be ignored since this effect can affect the decision to continue or discontinue statin medication, thereby potentially exposing the patient to cardiovascular risk. Therefore, it is essential to effectively identify the nocebo/drucebo effect using an objective approach, which contributes to avoiding affecting the progress of lipid-lowering therapy in patients. The International Lipid Expert Panel (ILEP) has published guidelines that can assist physicians and patients in overcoming the nocebo problem. The first step was to assess patients' myopathy symptoms. The National Lipid Association (NLA) proposed a Statin Myalgia Clinical Index (SMCI) in 2014, and revised it and renamed it as Statin Associated Muscle Symptoms Clinical Index (SAMS-CI) in 2017 <xref ref-type="bibr" rid="b0545">[109]</xref>. The index has been validated through clinical application, and although it cannot directly determine patients with true SAMS, it could screen out patients with unlikely SAMS <xref ref-type="bibr" rid="b0545">[109]</xref>. The relevant tables are shown in <xref ref-type="fig" rid="f0020">Fig. 4</xref>. Secondly, factors that may increase the risk of SAMS were carefully evaluated, and if the presence of these risks was confirmed, the indication for statins for this patient was assessed and a rational clinical management strategy is made by (I) adjusting the dosage with a lower dose of another statin or a longer-acting statin that is given in less than the daily dose;（II）Alternative medication: Major alternative drugs include ezetimibe <xref ref-type="bibr" rid="b0550">[110]</xref>, PCSK9 mAb <xref ref-type="bibr" rid="b0555">[111]</xref>, bempedoic acid <xref ref-type="bibr" rid="b0555">[111]</xref>, inclisiran <xref ref-type="bibr" rid="b0560">[112]</xref> and evinacumab for homozygous familial hypercholesterolemia <xref ref-type="bibr" rid="b0565">[113]</xref>;（III）combination therapy:Ezetimibe or bempedoic acid + long-acting statin combination <xref ref-type="bibr" rid="b0535">[107]</xref>, <xref ref-type="bibr" rid="b0550">[110]</xref>, <xref ref-type="bibr" rid="b0570">[114]</xref>, <xref ref-type="bibr" rid="b0575">[115]</xref>.<fig id="f0020" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Clinical management program for statin-associated liver injury.</p></caption><graphic id="lk00020" orientation="portrait" position="float" xlink:href="gr4.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0120">In addition, numerous investigators have proposed that side effects can be minimised by reducing the frequency of statin administration such as alternate-day, which only applies to statins with a long half-life such as atorvastatin or rosuvastatin, but this method has not been validated in cardiovascular event prevention. For patients with SI, replacement with other drugs such as PCSK9 inhibitors or bempedoic acid, a drug approved by the FDA, is an alternative approach to achieve target LDL-C levels <xref ref-type="bibr" rid="b0580">[116]</xref>, <xref ref-type="bibr" rid="b0585">[117]</xref>. Another expert opinion paper suggested that some nutraceuticals with lipid-lowering activity, such as berberine, red yeast rice, artichoke, bergamot, phytosterols and stanols alone or in combination with each other may hold promise as alternative therapies to statins <xref ref-type="bibr" rid="b0590">[118]</xref>, <xref ref-type="bibr" rid="b0595">[119]</xref>. These nutraceuticals may not only exert significant lipid-lowering activity, but also exhibit beneficial effects such as improving endothelial dysfunction, antioxidant and anti-inflammatory properties,etc. <xref ref-type="bibr" rid="b0600">[120]</xref>. For physical activity, studies have shown that the exercise history, the type, frequency, duration, and intensity of exercise have different effects on SAMS, and clinicians should balance the benefits and risks of statin therapy with physical activity to provide an individualised optimal evidence-based treatment regimen <xref ref-type="bibr" rid="b0540">[108]</xref>.</p></sec></sec><sec id="s0060"><title>Nephrotoxicity</title><p id="p0125">There was not sufficient evidence from nephrotoxicity studies with statins to prove that statins increase the risk of kidney injury in patients. However, the course of statin-induced rhabdomyolysis was often accompanied by myoglobinuria. This was due to the massive release of myoglobin into the blood as a result of muscle lysis, and the increased levels of myoglobin in the blood can lead to mechanical obstruction and acute necrosis of the renal tubules, which can lead to the development of acute renal failure <xref ref-type="bibr" rid="b0605">[121]</xref>. Teutonico et al. reported that a 45-year-old patient, taking both cyclosporine A and simvastatin, developed acute renal failure caused by myoglobinuria <xref ref-type="bibr" rid="b0610">[122]</xref>. Petreski et al <xref ref-type="bibr" rid="b0615">[123]</xref>, Kar et al. <xref ref-type="bibr" rid="b0620">[124]</xref>, Medina-Romero et al. <xref ref-type="bibr" rid="b0625">[125]</xref> and Frydrychowicz et al. <xref ref-type="bibr" rid="b0630">[126]</xref> have reported similar cases. In a 2019 <italic toggle="yes">meta</italic>-analysis that included 94,283 patients, not only did statins lead to an increased risk of patients developing myopathy, hepatic impairment, and type 2 diabetes, the results also showed that statins increased the risk of developing renal dysfunction compared to placebo, with an incidence of renal dysfunction in patients within 10 years of statin treatment of roughly 16 cases per 1000 people <xref ref-type="bibr" rid="b0635">[127]</xref>. In addition to this, there were also studies that showed an association between statins and renal cell carcinoma (RCC). Wilson et al. found that although statins did not increase the risk of developing RCC through a case analysis of 661 patients with RCC. After taking gender into account, further analysis revealed that there was no correlation between the risk of RCC and statins in female patients, but statin use significantly increased the risk of RCC in male patients <xref ref-type="bibr" rid="b0640">[128]</xref>. Overall, statins are relatively safe for patients' kidney function, however, medical attention is still essential if symptoms of kidney disease develop, and some statin doses should be reduced in patients with severe renal impairment.</p></sec><sec id="s0065"><title>Associated liver injury</title><p id="p0130">Statin-associated liver injury (SILI) is sometimes defined as elevation ≥ 5-fold upper limit of normal (ULN) levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels alone, or alkaline phosphatase (ALP) &gt; 2x ULN or AST &gt; 3x ULN along with total bilirubin (TBIL) &gt; 2x ULN <xref ref-type="bibr" rid="b0645">[129]</xref>. Approximately 3.1 % and 2.8 % of patients treated with statins have abnormally elevated aminotransferases, but there does not appear to be a correlation between elevated aminotransferases and liver injury. The majority of patients with elevated aminotransferases who continue to take the drug return to normal after discontinuing the drug <xref ref-type="bibr" rid="b0650">[130]</xref>. Liver damage occurs in only about 1 per 1000 to 1 per 10 000 of patients with transaminase abnormalities, and the latency period for liver damage ranges from 1 month to 10 years <xref ref-type="bibr" rid="b0655">[131]</xref>. Statin-associated liver injury is mainly categorized into hepatocellular, complex and cholestatic liver injury. In addition to this, cases of autoimmune hepatitis have been reported in patients <xref ref-type="bibr" rid="b0170">[34]</xref>, <xref ref-type="bibr" rid="b0660">[132]</xref>. Cases of statin-associated hepatotoxicity were very rare in a large population-based study. Liver injury occurred in only 19/100,000 people treated with statins, and there was no conclusive evidence that elevated ALT was necessarily associated with an increased risk of statin-associated liver injury <xref ref-type="bibr" rid="b0665">[133]</xref>. In addition, an investigation of statin-related liver injury was reported by Russo et al. They initially screened 1188 patients with suspected drug-related liver injury from patients with liver injury between 2004 and 2012, and only 22 (1.85 %) of these patients were finally recognized as statin-associated liver injury by further identification screening. Among them, hepatocellular liver injury was predominant, and most of them were mild or moderate injury. Some of them were accompanied by symptoms of jaundice, and the vast majority of cases were self-limiting and did not develop into chronic liver injury or death <xref ref-type="bibr" rid="b0670">[134]</xref>. However, there have been reports of statin-treated patients having permanently discontinued treatment due to elevated ALT, including with atorvastatin and simvastatin <xref ref-type="bibr" rid="b0080">[16]</xref>. Statins can cause a return of significant liver injury in patients with recovered liver function in SILI <xref ref-type="bibr" rid="b0675">[135]</xref>. Therefore, statins should be used with caution in patients who have developed liver damage.</p><p id="p0135">Although the side effects of statins in terms of liver injury are well recognized, the extremely low prevalence of these side effects has led to a number of clinical trials with small sample sizes in which statins were not found to cause liver injury in patients <xref ref-type="bibr" rid="b0645">[129]</xref>, <xref ref-type="bibr" rid="b0680">[136]</xref>. In contrast to statins showing potentially liver-damaging side effects, some studies have shown that statins also have a somewhat protective effect against some chronic liver diseases <xref ref-type="bibr" rid="b0685">[137]</xref>. These include improvement of cell viability, prevention of ischemia/reperfusion injury, improvement of microvascular function, and protection against multiple causes of liver cirrhosis <xref ref-type="bibr" rid="b0690">[138]</xref>, <xref ref-type="bibr" rid="b0695">[139]</xref>. In one study, simvastatin reduced mortality in liver transplant patients and improved graft survival, and also minimized the risk of complications after liver transplantation <xref ref-type="bibr" rid="b0700">[140]</xref>.</p><sec id="s0070"><title>The Potential Mechanism</title><sec id="s0075"><title>Influence on functional protein expression</title><p id="p0140">Various studies have found that statins cause changes in the levels of several functional proteins in hepatocytes along with significant liver lesions. For example, Steiner et al. showed that significant liver changes occurred in male F344 rats after administration of a high dose of fluvastatin (24 mg/kg) for seven consecutive days. Significant changes in 58 liver-related proteins were seen in the rats after administration of fluvastatin. These included HMG-CoA reductase upstream and downstream proteins, carbohydrate metabolism-related enzymes (e.g., fructose-1,6-bisphosphatase, pyruvate kinase, etc.), structural proteins of the skeleton (keratin I cytoskeleton 18 and keratin II cytoskeleton 8), as well as calcium homeostasis, protease-associated cellular stress proteins (senescence marker protein-30), and other proteases <xref ref-type="bibr" rid="b0705">[141]</xref>. Hareedy et al. showed that the plasma levels of total protein, albumin and globulin were significantly lower in the simvastatin treated group of male rats compared with the normal group. Meanwhile, histopathological examination revealed that the central vein and hepatic sinusoids of rats' livers were dilated, and some nuclei of hepatocytes were also found to be diseased and appeared scorched. This suggests that simvastatin 30 mg/kg/day has a certain damaging effect on the liver of rats <xref ref-type="bibr" rid="b0710">[142]</xref>.</p></sec><sec id="s0080"><title>Genetic polymorphisms</title><p id="p0145">Transporters encoded by the <italic toggle="yes">SLCO1B1</italic> and <italic toggle="yes">ABCG2</italic> genes control the uptake and efflux of statins, and loss-of-function polymorphisms in both are highly associated with statin-associated hepatotoxicity <xref ref-type="bibr" rid="b0715">[143]</xref>. The OATP1B1 transporter encoded by the <italic toggle="yes">SLCO1B1</italic> gene is a mediator for the transport of all statins into the liver. Variation in OATP1B1 function as a result of a locus variant in the <italic toggle="yes">SLCO1B1</italic> gene will directly affect the efficiency of statin uptake in the liver. In contrast, breast cancer resistance protein (BCRP) encoded by ABCG2 is an efflux transporter, which also influences statin concentrations in the liver <xref ref-type="bibr" rid="b0050">[10]</xref>. Merćep et al. found that the proportion of variant carriers of <italic toggle="yes">SLCO1B1</italic> and <italic toggle="yes">ABCG2</italic> genes was significantly higher in the case group of patients with rosuvastatin adverse events, which were mainly myotoxicity, than in the normal group <xref ref-type="bibr" rid="b0160">[32]</xref>. In addition to this, other transporter-related genes can similarly play a role in liver injury with statins. Among them, Fukunaga et al. also found that the rs2032582 SNP in ABCB1 was associated with statin-associated liver injury in Japanese and Caucasian populations <xref ref-type="bibr" rid="b0720">[144]</xref>. In addition, it has been shown that the <italic toggle="yes">ABCC2</italic> gene was associated with the risk of statin-associated liver injury <xref ref-type="bibr" rid="b0060">[12]</xref>. OATP1B1 transports statins into hepatocytes for metabolism and clearance and OATP1B1 is the main uptake transporter of SV acid in the liver, and inhibition of its uptake function can increase the systemic exposure of SV acid. Thus, more SVL enters the lipid bilayer of the hepatocyte membrane, which attenuates hepatocyte membrane fluidity and permeability and promotes hepatocyte stress <xref ref-type="bibr" rid="b0190">[38]</xref>. This in turn may result in elevated transaminases and liver injury.The hepatocellular uptake of most statins is dependent on OATP1B1 activity and some statins are metabolized in the liver by CYP450. If taken with drugs that inhibit the CYP450 metabolizing enzymes, this may lead to an increase in plasma statin concentrations, increasing the risk of myopathy in the patient <xref ref-type="bibr" rid="b0190">[38]</xref>.</p></sec><sec id="s0085"><title>Mitochondrial function</title><p id="p0150">In addition, liver mitochondria are abundant and highly active in metabolism, and simvastatin interrupts the mitochondrial electron transport chain and reduces the efficiency of fatty acid oxidation, thereby inhibiting mitochondrial respiration, resulting in toxic effects on the liver <xref ref-type="bibr" rid="b0195">[39]</xref>. Simvastatin also decreases mitochondrial membrane puncta and inhibits prenylation of signaling proteins such as the Ras superfamily. At the same time, it also increases the expression of cytochrome <italic toggle="yes">C</italic> pro-apoptotic proteins <xref ref-type="bibr" rid="b0315">[63]</xref>. Statins can also lead to liver cell injury by inhibiting coenzyme Q10, which further diminishes the antioxidant effect on liver cells. Thus, liver injury caused by atorvastatin may be alleviated when coenzyme Q10 is used in combination <xref ref-type="bibr" rid="b0725">[145]</xref>. Pek et al. investigated the role of ubiquinol in simvastatin induced liver injury by supplementing ubiquinol (reduced coenzyme Q10) along with simvastatin treatment. The results showed that long-term supplementation with ubiquinol reduced ALT and ALP in patients. In addition, the expression levels of various miRNAs, such as miR-15a and miR-21, were found to correlate with ALT and/or ALP, a finding that was also validated in an in vitro HepG2 hepatocyte cell line. Therefore, the investigators suggested that ubiquinol supplementation might ameliorate liver injury with simvastatin and that miRNAs could serve as a class of markers of hepatotoxicity <xref ref-type="bibr" rid="b0200">[40]</xref>.</p></sec><sec id="s0090"><title>Pro-apoptotic effect</title><p id="p0155">Kubota et al. used artificially cultured human hepatocytes to examine the toxic effects of different statins. Lipophilic statins such as simvastatin, cerivastatin and atorvastatin were found to have a certain degree of hepatocyte toxicity, with simvastatin being the most toxic and cerivastatin the second most toxic. However, the hydrophilic pravastatin was not hepatocytotoxic. Subsequent studies with simvastatin revealed that simvastatin was able to inhibit the irreversible Caspase-3 inhibitor, zDEVD-fmk through DNA fragmentation, which in turn led to an increase in the level of caspase-3 expression in hepatocytes, and further activated caspase-9 and caspase-8 and promoted apoptosis in hepatocytes <xref ref-type="bibr" rid="b0205">[41]</xref>.</p></sec></sec><sec id="s0095"><title>Intervention</title><p id="p0160">Statin-associated liver injury is generally self-limiting. That is, the associated symptoms gradually resolve after discontinuation of the drug. Because of the presence of certain immune properties, some patients may need to take steroids to accelerate the resolution of liver injury symptoms. Patients with normal bilirubin and aminotransferase levels &lt; 3 times ULN may have non-alcoholic fatty liver disease (NAFLD) and may continue to take statins, but regular liver function tests are necessary. In patients with elevated bilirubin and aminotransferase levels &gt; 3 times ULN, statin therapy should be immediately discontinued, and the etiology of hyperbilirubinemia should be evaluated. In patients with transaminases &gt; 3 times ULN who maintain chronically elevated transaminases, statin therapy should be discontinued and the use of non-statins or other statins at lower doses should be considered after clinical safety assessment. If the patient also has jaundice, repeated liver tests are required. If the patient is also suffering from coagulation disorders, hospitalization for observation is usually required <xref ref-type="bibr" rid="b0730">[146]</xref>. Specific guidance is shown in <xref ref-type="fig" rid="f0020">Fig. 4</xref>. In addition to clinical management, some drugs have been found to have a certain ameliorative effect on drug-induced liver injury, including N-acetylcysteine, bisabolol, silymarin, and isoglycyrrhizinate. However, these have poor drug safety and limited efficacy, so the need for supplemental therapy should be based on the clinician's medication guidelines <xref ref-type="bibr" rid="b0735">[147]</xref>.</p></sec></sec><sec id="s0100"><title>Glucose abnormality</title><p id="p0165">Retrospective studies have found that statin therapy resulted in a significantly higher risk of developing new-onset diabetes mellitus (NODM) and was strongly associated with the potency and dose of the statin. The risk of diabetes was further elevated in patients with abnormalities of basal glucose homeostasis, particularly high baseline glucose, and the risk of NODM was further elevated with long-term use <xref ref-type="bibr" rid="b0740">[148]</xref>, <xref ref-type="bibr" rid="b0745">[149]</xref>. The increased risk of NODM was first seen in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) <xref ref-type="bibr" rid="b0750">[150]</xref>. The study, which included 17,802 patients without diabetes, was the first comparative study to find that rosuvastatin significantly increased the relative risk of newly diagnosed diabetes. In particular, patients treated with rosuvastatin had a 3 % chance of developing newly diagnosed diabetes, compared to 2.4 % for those treated with placebo, and there was a significant difference between the two groups <xref ref-type="bibr" rid="b0750">[150]</xref>. In addition, an analysis that included 91,140 patients researchers found that patients treated with statins had a 9 % higher risk of a diabetes diagnosis compared to those treated with placebo <xref ref-type="bibr" rid="b0755">[151]</xref>. A subsequent <italic toggle="yes">meta</italic>-analysis, comparing statins and placebo, concluded that the risk of developing diabetes was 12 % higher with statin therapy. Further analysis revealed that statin therapy may also be associated with increased waist circumference, weight gain, and increased insulin levels <xref ref-type="bibr" rid="b0760">[152]</xref>. For patients with CAD receiving high-intensity statin therapy, the LODESTAR randomized clinical trial found no significant difference in the incidence of NODM in 2377 CAD patients treated with high-intensity atorvastatin or rosuvastatin. This study demonstrated that when the risk of NODM with the two statin treatments was assessed using low-density lipoprotein cholesterol (LDL-C) levels, the risk of NODM with statins began to increase once LDL-C levels fell below 70 mg/dL <xref ref-type="bibr" rid="b0765">[153]</xref>. Data from a clinical study showed an increased risk of diabetes in patients with renal transplants who were concomitantly using statins <xref ref-type="bibr" rid="b0770">[154]</xref>. Although the extent to which different statin compounds affect a patient's risk of developing diabetes varies across the multiple <italic toggle="yes">meta</italic>-analyses mentioned above, it is certain, that statins increase the risk of developing newly diagnosed diabetes to varying degrees, but it is a general effect of most statins <xref ref-type="bibr" rid="b0775">[155]</xref>. It has to be emphasized that the therapeutic role of statins in cardiovascular diseases cannot be ignored, and the benefits exceed the side effects of statins for most patients.</p><sec id="s0105"><title>The Potential Mechanism</title><p id="p0170">The finding that statins increase the risk of diabetes has been confirmed by a number of studies. However, the mechanism was not clear, and research now suggested that the mechanism may be related to inhibition of insulin release, reduction of insulin sensitivity, and genetic polymorphisms.</p><sec id="s0110"><title>The inhibition on insulin release</title><p id="p0175">Statins caused abnormal insulin signaling, which in turn lead to decreased adipocyte differentiation and suppression of pancreatic β-cell secretion <xref ref-type="bibr" rid="b0095">[19]</xref>. Cederberg et al. found that after treatment with simvastatin or atorvastatin, patients had a significantly higher risk of developing NODM. In a further study, it was found that treatment with simvastatin or atorvastatin also reduced the level of insulin secretion in patients in a dose-dependent manner, and there was a decrease in insulin sensitivity <xref ref-type="bibr" rid="b0780">[156]</xref>. Further mechanistic studies have found that statins may also inhibit mitochondrial respiration by decreasing mitochondrial complex II activity, which in turn suppressed mitochondrial respiration and lead to a decrease in ATP levels in the cell membrane and inhibition of the function of L-type Ca<sup>2+</sup> channels <xref ref-type="bibr" rid="b0785">[157]</xref>. Simvastatin inhibits L-type Ca<sup>2+</sup> channels in pancreatic β-cells, and the resulting reduction in cholesterol levels may also alter Ca<sup>2+</sup> channel configuration. The physiological function of Ca<sup>2+</sup> channels in pancreatic β-cells includes a voltage-dependent regulation of Ca<sup>2+</sup> entry into pancreatic β-cells, which promotes the pancreatic β-cells' insulin secretion <xref ref-type="bibr" rid="b0790">[158]</xref>. The effect of Ca<sup>2+</sup> channels involved in insulin release and the mechanism of statin intervention are shown in <xref ref-type="fig" rid="f0025">Fig. 5</xref>.<fig id="f0025" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Statins inhibit insulin release by inhibiting respiration and altering calcium channels.</p></caption><graphic id="lk00025" orientation="portrait" position="float" xlink:href="gr5.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></sec><sec id="s0115"><title>Reduced insulin sensitivity</title><p id="p0180">The <italic toggle="yes">meta</italic>-analysis by Baker et al. found that statins cause some effect on insulin sensitivity, but not consistently across statins. For example, simvastatin significantly reduced insulin sensitivity, while pravastatin improved insulin sensitivity, and atorvastatin and rosuvastatin were able to reduce insulin sensitivity to some extent, but there was no significant difference when compared to the placebo group. However, when the simvastatin, atorvastatin and rosuvastatin groups were combined and then compared with the placebo group, a noteworthy reduction in insulin sensitivity was observed in the statin group <xref ref-type="bibr" rid="b0215">[43]</xref>. The mechanism by which statins reduce insulin sensitivity has not been well studied. Betteridge and Carmena found that statins may have a damaging effect on the pancreas through calcium channels, reducing insulin sensitivity <xref ref-type="bibr" rid="b0795">[159]</xref>. Henriksbo and Schertzer suggested that statins also increase levels of inflammatory factors such as IL-1β through the NLRP3 pathway, leading to insulin resistance. Moreover, statins also decreased protein prenylation, promoted ATP release and potassium efflux, all of which synergistically contribute to the activation of the NLRP3 pathway <xref ref-type="bibr" rid="b0800">[160]</xref>.</p></sec><sec id="s0120"><title>Genetic polymorphisms</title><p id="p0185">Genetic polymorphisms have been associated with statin-associated diabetes risk. For example, a Mendelian randomization study identified 2 SNPs in the HMGCR gene that play an important role in statin antagonism of HMGCR. For each additional allele, there was a decrease in LDL-C of 0.06 mmol/L and an increase in body mass of 0.3 kg, as well as slight increases in waist circumference, blood glucose, and insulin levels. These changes were often accompanied by a risk of NODM of approximately 2 %-6% <xref ref-type="bibr" rid="b0805">[161]</xref>. Impaired early insulin release or impaired conversion of proinsulin to insulin was found in non-diabetic Finnish men with the following SNPs: TCF7L2, SLC30A8, HHEX, CDKN2B, CDKALI, MTNR1B, KCNJ11 and IGF2BP2 <xref ref-type="bibr" rid="b0810">[162]</xref>. As insulin resistance progresses, genetic polymorphisms could lead to inactivation of HMG-CoA reductase, which in turn could lead to a significant decrease in LDL-C and an increase in body mass.</p></sec></sec><sec id="s0125"><title>Intervention</title><p id="p0190">There have been sufficient studies to confirm that statins are strongly associated with NODM and that the incidence of NODM varies by type and dose of statin. However, the risk of NODM from statins is minimal compared to the cardiovascular protection benefits. Overall, however, it is important to have a scientific assessment of the risk factors for statins, actively treat complications such as obesity and hypertension, and regularly test blood glucose when receiving statins. Additionally, adherence to moderate exercise and a healthy diet can reduce the risk of NODM along with the benefits of statin therapy. Statins remain the preferred choice of lipid-lowering agents, however, with the advent of ezetimibe, a cholesterol uptake inhibitor, combinations may be considered to reduce the risk of statin dose-dependent NODM. It was found that in hypertensive patients given a combination of telmisartan and rosuvastatin for 6 months, the insulin resistance index decreased by 29 % from basal values, and fasting glucose and HbA1c did not change significantly before and after treatment, suggesting that the combination of telmisartan may be able to reduce the risk of NODM caused by statins <xref ref-type="bibr" rid="b0815">[163]</xref>. Overall, the dosage needs to be carefully controlled when using statins.</p></sec></sec><sec id="s0130"><title>Central nervous system</title><p id="p0195">In addition, other researchers have found that statins also have some effects on the central nervous system. For example, statins could affect cognitive function <xref ref-type="bibr" rid="b0220">[44]</xref>, <xref ref-type="bibr" rid="b0820">[164]</xref>. Although early case report of statins on cognitive dysfunction were not plentiful, they were not reported as side effects of statins <xref ref-type="bibr" rid="b0825">[165]</xref>. However, with the widespread use of statins, more and more relevant cases have been identified. It has been found that most of these cognitive deficits are one-time events, with recovery upon discontinuation of the drug and relapse upon resumption of the drug <xref ref-type="bibr" rid="b0830">[166]</xref>. In a double-blind investigation by Muldoon et al., it was concluded that lovastatin in the treatment of hypercholesterolemia did not severely altering cognitive function, but was confirmed to cause a decrease in patients attention and neuropsychological test scores <xref ref-type="bibr" rid="b0175">[35]</xref>. Sahebzamani et al.estimated the risk of cognitive impairment due to statins to be roughly between 0.1–1 % based on data reported in relation to the AERs database. In comparison, simvastatin and atorvastatin were most widely used worldwide. Therefore, the more cases of cognitive impairment caused by these two drugs were reported, their true incidence was about 3000–30,000 cases per year and the correlation between lipophilic statins and cognitive impairment could be higher <xref ref-type="bibr" rid="b0220">[44]</xref>. In a controlled clinical study, that involved giving 283 people placebo, 10 mg simvastatin and 40 mg simvastatin, respectively, the administration of simvastatin resulted in a slight decrease in cognitive performance compared to placebo. There were also case reports of cognitive impairment in patients treated with 40 mg of simvastatin <xref ref-type="bibr" rid="b0835">[167]</xref>. There were also findings suggesting that statins play a role in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Further study of the mechanism may be that statins could inhibit the accumulation of β-amyloid by reducing cholesterol lipid content, which in turn may play a role in the improvement of Alzheimer's disease <xref ref-type="bibr" rid="b0840">[168]</xref>. In addition, it has been shown that statins have the ability to reduce the expression levels of inflammatory factors such as IL-1β and IL-6 in the brain. This supported the idea that statins had a protective effect on the central nervous system <xref ref-type="bibr" rid="b0220">[44]</xref>.</p><sec id="s0135"><title>The Potential Mechanism</title><p id="p0200">The mechanism of the effect of statins on cognitive impairment has been of wide interest to researchers. Most studies suggest that statins have less effect on the central nervous system cholesterol compared to the peripheral circulation. The main reason for this was that astrocytes and neuronal cells in the adult brain could synthesize cholesterol from scratch, and free cholesterol could be recycled after neuronal death. In contrast, the human brain did not metabolize cholesterol as much in adult humans <xref ref-type="bibr" rid="b0845">[169]</xref>. The half-life of cholesterol in the brain could basically reach half a year to five years, and the cholesterol level in the brain was relatively stable, with extremely small changes from day to day <xref ref-type="bibr" rid="b0180">[36]</xref>.</p><p id="p0205">Although statin drugs do not cause dramatic changes in cholesterol levels in the central nervous system, there were experimental result showed that long-term use of statin drugs decreases cholesterol levels in the central nervous system. 24S-hydroxycholesterol was a specific cholesterol metabolite in the brain, and it was able to cross the blood–brain barrier and enter the body's circulation to be detected, so it was used as a marker for cholesterol levels in the brain in a number of studies. It has been shown that long-term use of statins leads to a decrease in 24S-hydroxycholesterol levels in plasma and cerebrospinal fluid. There were experiments that confirmed that long-term statins could indeed change the level of cholesterol expression in the brain. Since cholesterol was closely related to the formation of neuromyelin sheaths, neurological signaling, mitochondrial function, and synaptic development, which leads to cognitive impairment in patients who were on long-term statin medication <xref ref-type="bibr" rid="b0225">[45]</xref>, <xref ref-type="bibr" rid="b0850">[170]</xref>, <xref ref-type="bibr" rid="b0855">[171]</xref>.</p><p id="p0210">However, the effect of statins on cholesterol concentrations in the brain was not as direct and rapid as that of peripheral cholesterol, plus the need for long-term administration of the drug to affect cholesterol concentrations in the brain. Thus, it was considered that the effects of statins on the central nervous system were mainly due to their direct effects in the brain. Considering that statins have different lipid solubility, this mean that lipophilic compounds such as lovastatin and fluvastatin were more likely to cross the blood–brain barrier, but several in vivo and ex vivo studies have found that hydrophilic statins were just as capable of entering the central nervous system <xref ref-type="bibr" rid="b0860">[172]</xref>. For example, pravastatin, as a hydrophilic compound, could be detected in human cerebrospinal fluid, and the reason for this phenomenon may be that hydrophilic statins cross the blood–brain barrier through OATP1B1 or monocarboxylate transporters, etc. <xref ref-type="bibr" rid="b0865">[173]</xref>. Since lipophilic statins could directly cross the blood–brain barrier, they were more likely to accumulate in the brain than hydrophilic statins, which was consistent with the phenomenon of “higher lipophilic statins and cognitive impairment” <xref ref-type="bibr" rid="b0870">[174]</xref>. Similarly, due to the brain's ability to synthesize cholesterol, cholesterol levels in the brain gradually return after the drug has been withdrawn. Consequently, the cognitive impairment caused by low levels of cholesterol would gradually recover, which was consistent with the transient nature of the cognitive impairment caused by statins <xref ref-type="bibr" rid="b0830">[166]</xref>. As mentioned earlier, statins with different lipid solubility can enter the brain in different ways, then, there are differences in the pharmacokinetics of different statin compounds in the CNS. This may account for the differences in the studies of statins on the CNS, but this was not supported by sufficient findings, which may provide new ideas for future clinical research.</p></sec></sec><sec id="s0140"><title>Other impacts</title><p id="p0215">In addition, statins have been shown to increase the risk of hemorrhagic stroke in patients with cerebrovascular disease, with a 66 % increase in the risk of hemorrhagic stroke in the atorvastatin-treated group compared with the placebo group in one study <xref ref-type="bibr" rid="b0875">[175]</xref>. A systematic review and <italic toggle="yes">meta</italic>-analysis of large randomised controlled trials (≥1000 patients with ≥ 2 years of follow-up) showed that lowering LDL-C therapy, including statin therapy, slightly increased the risk of haemorrhagic stroke events <xref ref-type="bibr" rid="b0880">[176]</xref>. A study of risk factors for statin-associated hemorrhagic stroke showed that a history of hemorrhagic stroke, males, and older adults were risk factors <xref ref-type="bibr" rid="b0885">[177]</xref>. In addition to these risk factors, statin therapy in patients with atherosclerosis could instead greatly reduce the risk of thrombotic stroke. Meanwhile, in a trial combining simvastatin and ezetimibe, simvastatin alone was found to increase the risk of hemorrhagic stroke.However, adjunctive treatment with ezetimibe was associated with a small reduction in the risk of hemorrhagic stroke compared with simvastatin alone <xref ref-type="bibr" rid="b0100">[20]</xref>.</p><p id="p0220">In addition, few studies found that statin therapy was associated with potentially fatal lupus-like reactions <xref ref-type="bibr" rid="b0890">[178]</xref> In addition, studies have found that statins also exhibited some association with the development of certain tumors. For example, a cohort study showed that statin use after a diagnosis of gastric cancer was associated with a lower risk of cancer-specific death. This study indicated that the use of statins for more than 6 months was associated with increased survival from gastric cancer compared to no statin use. However, it has also been shown that reduced statin use reduces the risk of gastric cancer and improves overall survival (OS) in patients with gastric cancer, but the mechanism of action is unclear <xref ref-type="bibr" rid="b0895">[179]</xref>, <xref ref-type="bibr" rid="b0900">[180]</xref>. In addition, statins have been shown to potentially reduce the risk of pancreatic cancer and improve survival in patients with metabolic syndrome and pancreatic cancer. Preclinical studies have shown that statins have antitumor effects in both pancreatic cancer cell lines and in vivo animal models. In addition to delaying the progression of pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma (PDAC), and also inhibiting PDAC formation in conditional K-Ras mutant mice <xref ref-type="bibr" rid="b0905">[181]</xref>.</p><p id="p0225">In conclusion, there were fewer reports of these adverse effects caused by statin use. The exact mechanism of action was unclear, but based on the current evidence, the cardioprotective benefits of statins still outweigh the risks, and it was important to prevent and treat adverse effects when necessary.</p></sec><sec id="s0145"><title>Conclusions and perspectives</title><p id="p0230">Statins are one of the most widely used lipid-lowering drugs, which can inhibit the occurrence of cardiovascular and cerebrovascular diseases by effectively lowering blood lipids and stabilizing intravascular plaque. Overall, statins have a high safety profile, but with the large clinical use population, their adverse effects are gradually increasing. The efficacy and side effects of statins vary significantly among individuals, and are mainly influenced by genotype and pathophysiology. This article mainly reviewed the clinical manifestations, risk factors, interactions, pathogenesis, and interventions of common adverse effects of statins in clinical practice. with a view to reducing statin adverse effects. This will provide important guidance for the rational and safe use of statins, and can further provide important reference for the novel design and development of statins.</p><p id="p0235">Researchers have made some breakthrough progress in exploring the mechanistic studies of adverse effects of statins. For example, (I) SAMS may be closely related to the <italic toggle="yes">SLCO1B1</italic> gene variants, mitochondrial damage, regulation of AKT, Ca<sup>2+</sup> level, amino acid aminotransferase (GATM), and regulation of GTPase. However, there is no consensus on the precise diagnostic criteria and incidence of SAMS, the pathologic mechanisms of SAMS are more complex and not yet fully understood. Therefore, further large-scale clinical studies are needed. The most effective interventions for SAMS are the reduction or discontinuation of statins and the use of alternative therapies, such as ezetimibe and PCSK9 inhibitors. Other medications (coenzyme Q10) lack sufficient evidence to support them. (II) statin drugs for patients with impaired renal function are relatively safe. However, the effects on renal function need to be further explored. (III) For the hepatotoxicity of statins there is a more significant correlation mainly with the expression of liver-related proteins, <italic toggle="yes">SLCO1B1</italic> and <italic toggle="yes">ABCG2</italic> gene polymorphisms, mitochondrial damage and DNA levels. However, statin-associated liver injury will be gradually relieved after stopping the drug. (IV) Statin drug type and dosage, age, race, and underlying disease increase the risk of NODM. The pathologic mechanism of NODM caused by statins may be related to the secretion of pancreatic islet B cells, the influence of insulin sensitivity and genetic polymorphisms, but the deeper mechanism needs to be further explored. Therefore, before receiving statins, make a scientific assessment of their risk factors, at the same time, avoid drug interactions can reduce the incidence of such diseases. (V) With the continuous implementation of the use of statins in clinical practice, some adverse reactions may occur in the central nervous system, with insomnia, sensory abnormalities, dizziness, memory dysfunction and other common symptoms. This may be related to the fact that statins can inhibit the synthesis of cholesterol in the body, but there is no definite clinical evidence for cognitive dysfunction, which still needs to be further explored.</p><p id="p0240">In short, lifestyle interventions are the basis for lipid lowering, and moderate-intensity statins are used as the starting therapy for achieving lipid lowering. When LDL-C cannot be achieved with moderate-intensity statin therapy, it can be combined with cholesterol absorption inhibitor therapy. If LDL-C targets cannot be achieved with moderate-intensity statins and cholesterol absorption inhibitors, PCSK9 inhibitors can be combined. Thus, in future clinical treatment, depending on the specific clinical reality, a new LDL-C target value may be considered to reduce the risk of adverse events without increasing cardiovascular events, it may provide new ideas for future clinical treatment. In addition, the occurrence of statin adverse reactions is closely related to <italic toggle="yes">SLCO1B1</italic> gene polymorphism. For patients at high and very high risk of ASCVD, lipid-lowering fixed-dose combinations such as statins/ezetimibe, statins/fibrates and bempedoic acid/ezetimibe represent an optional approach that could provide better control of plasma lipids, ensure a higher adherence and improve the prognosis of ASCVD, as well as significantly reduce the risk of major adverse cardiovascular events <xref ref-type="bibr" rid="b0910">[182]</xref>. In addition, it is worth noting that retrospective cohort studies have shown that the benefit of statin therapy in high-risk elderly cardiovascular patients tends to depend on their baseline cardiovascular risk. As the baseline cardiovascular risk increases, statin prescription decreases progressively. For high-risk elderly patients, the maximum therapeutic benefit of implementation of statin therapy may not be fully realised. It is necessary for physicians to appropriately adjust their prescribing behaviors based on the risk profile of elderly patients <xref ref-type="bibr" rid="b0915">[183]</xref>. On the other hand, the elderly population is usually affected by multiple diseases such as dyslipidemia, hypertension and diabetes mellitus, thus requiring multiple medications. When other drugs are used in combination with statin, monitoring of elderly patients should be enhanced with careful consideration of the potential clinical benefits and risks. If necessary, the type of drug, dosage and dosing profile could be adjusted to minimize adverse effects caused by drug interactions <xref ref-type="bibr" rid="b0355">[71]</xref>.</p><p id="p0245">Thus, patients can use genetic testing to prejudge the type of metabolic rate and drug sensitivity of statins, to assist the clinic in rationally selecting lipid-lowering drugs and adjusting drug dosage.There is still a lot of uncharted territory for research on the relationship between statins and genetic factors, and in the future, more precise and individualized treatment plans can be given to patients by examining pharmacogenomics. We believe that statins will continue to play an important role in both the exploration of the mechanisms of atherosclerosis and the development of diversified combined lipid-lowering.</p></sec><sec id="coi005" sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0250">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation id="h0005" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Aday</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Almarzooq</surname><given-names>Z.I.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics—2022 update: a report from the american heart association</article-title><source>Circulation</source><volume>145</volume><issue>8</issue><year>2022</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIR.0000000000001052</pub-id><pub-id pub-id-type="pmid">35078371</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation id="h0010" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gencer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marston</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Im</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Sever</surname><given-names>P.</given-names></name><name name-style="western"><surname>Keech</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Efficacy and safety of lowering ldl cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials</article-title><source>Lancet</source><volume>396</volume><issue>10263</issue><year>2020</year><fpage>1637</fpage><lpage>1643</lpage><pub-id pub-id-type="pmid">33186535</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(20)32332-1</pub-id><pub-id pub-id-type="pmcid">PMC8015314</pub-id></element-citation></ref><ref id="b0015"><label>3</label><mixed-citation id="h0015" publication-type="other">Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. Jama. 2016 2016 Sep 27;316(12):1289-97.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/jama.2016.13985</pub-id><pub-id pub-id-type="pmid">27673306</pub-id></mixed-citation></ref><ref id="b0020"><label>4</label><element-citation id="h0020" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virani</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Westerman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kuebeler</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Akeroyd</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Cluster randomized trial of a personalized clinical decision support intervention to improve statin prescribing in patients with atherosclerotic cardiovascular disease</article-title><source>Circulation</source><volume>147</volume><issue>18</issue><year>2023</year><fpage>1411</fpage><lpage>2143</lpage><pub-id pub-id-type="pmid">36871214</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIRCULATIONAHA.123.064226</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation id="h0025" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahbaz</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koushki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Penson</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group><article-title>Regulatory t cells: possible mediators for the anti-inflammatory action of statins</article-title><source>Pharmacol Res</source><volume>149</volume><year>2019</year><object-id pub-id-type="publisher-id">104469</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.phrs.2019.104469</pub-id><pub-id pub-id-type="pmid">31577918</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation id="h0030" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taqueti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ridker</surname><given-names>P.</given-names></name></person-group><article-title>Lipid-lowering and anti-inflammatory benefits of statin therapy: more than meets the plaque</article-title><source>Circ Cardiovasc Imaging</source><volume>10</volume><issue>7</issue><year>2017</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIRCIMAGING.117.006676</pub-id><pub-id pub-id-type="pmcid">PMC5757307</pub-id><pub-id pub-id-type="pmid">28679526</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation id="h0035" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.L.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>I.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Statins improve endothelial function via suppression of epigenetic-driven endmt</article-title><source>Nat Cardiovasc Res</source><volume>2</volume><issue>5</issue><year>2023</year><fpage>467</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">37693816</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s44161-023-00267-1</pub-id><pub-id pub-id-type="pmcid">PMC10489108</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation id="h0040" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakakos</surname><given-names>A.E.G.G.</given-names></name></person-group><article-title>Statins and left ventricular function</article-title><source>Curr Pharm Des</source><volume>23</volume><issue>46</issue><year>2017</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.2174/1381612823666170926125754</pub-id><pub-id pub-id-type="pmid">28950829</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation id="h0045" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillip Owens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mackman</surname><given-names>N.</given-names></name></person-group><article-title>The antithrombotic effects of statins</article-title><source>Annu Rev Med</source><volume>65</volume><issue>1</issue><year>2014</year><fpage>433</fpage><pub-id pub-id-type="pmid">24422578</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1146/annurev-med-051812-145304</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation id="h0050" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper-DeHoff</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Niemi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Luzum</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Tarkiainen</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Straka</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>The clinical pharmacogenetics implementation consortium guideline for slco1b1, abcg2, and cyp2c9 genotypes and statin-associated musculoskeletal symptoms</article-title><source>Clin Pharmacol Ther</source><volume>111</volume><issue>5</issue><year>2022</year><fpage>1007</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">35152405</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/cpt.2557</pub-id><pub-id pub-id-type="pmcid">PMC9035072</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation id="h0055" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reith</surname><given-names>C.</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Armitage</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baigent</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Interpretation of the evidence for the efficacy and safety of statin therapy</article-title><source>Lancet</source><volume>388</volume><issue>10059</issue><year>2016</year><fpage>2532</fpage><lpage>2561</lpage><pub-id pub-id-type="pmid">27616593</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(16)31357-5</pub-id></element-citation></ref><ref id="b0060"><label>12</label><mixed-citation id="h0060" publication-type="other">Woo HI, Kim SR, Huh W, Ko JW, Lee SY. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy korean subjects. Drug Des Devel Ther. 2017 2017/1/1;11:1135-46.<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/DDDT.S131487</pub-id><pub-id pub-id-type="pmcid">PMC5391214</pub-id><pub-id pub-id-type="pmid">28435225</pub-id></mixed-citation></ref><ref id="b0065"><label>13</label><element-citation id="h0065" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonifacio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanvee</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Bouitbir</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krahenbuhl</surname><given-names>S.</given-names></name></person-group><article-title>The akt/mtor signaling pathway plays a key role in statin-induced myotoxicity</article-title><source>Biochim Biophys Acta</source><volume>1853</volume><issue>8</issue><year>2015</year><fpage>1841</fpage><lpage>2189</lpage><pub-id pub-id-type="pmid">25913013</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.bbamcr.2015.04.010</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation id="h0070" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lotteau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ivarsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Restagno</surname><given-names>D.</given-names></name><name name-style="western"><surname>Colyer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A mechanism for statin-induced susceptibility to myopathy</article-title><source>Jacc Basic Transl Sci</source><volume>4</volume><issue>4</issue><year>2019</year><fpage>509</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">31468006</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacbts.2019.03.012</pub-id><pub-id pub-id-type="pmcid">PMC6712048</pub-id></element-citation></ref><ref id="b0075"><label>15</label><mixed-citation id="h0075" publication-type="other">Jalal MM, Whyte CS, Coxon FP, Mutch NJ. Atorvastatin-mediated inhibition of prenylation of rab27b and rap1a in platelets attenuates their prothrombotic capacity and modulates clot structure. Platelets. 2023 2023 Dec;34(1):2206921.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/09537104.2023.2206921</pub-id><pub-id pub-id-type="pmid">37139869</pub-id></mixed-citation></ref><ref id="b0080"><label>16</label><mixed-citation id="h0080" publication-type="other">Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013 2013 Oct 9;168(4):3846-52.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ijcard.2013.06.024</pub-id><pub-id pub-id-type="pmid">24001698</pub-id></mixed-citation></ref><ref id="b0085"><label>17</label><element-citation id="h0085" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsheikh-Ali</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Karas</surname><given-names>R.H.</given-names></name></person-group><article-title>Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the united states food and drug administration adverse event reporting system)</article-title><source>Am J Cardiol</source><volume>99</volume><issue>3</issue><year>2007</year><fpage>379</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">17261402</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.amjcard.2006.08.044</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation id="h0090" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kah</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wustenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Sirma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Montalbano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ocker</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Selective induction of apoptosis by hmg-coa reductase inhibitors in hepatoma cells and dependence on p53 expression</article-title><source>Oncol Rep</source><volume>28</volume><issue>3</issue><year>2012</year><fpage>1077</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">22710979</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3892/or.2012.1860</pub-id></element-citation></ref><ref id="b0095"><label>19</label><mixed-citation id="h0095" publication-type="other">Yaluri N, Modi S, Lopez RM, Stancakova A, Kuusisto J, Kokkola T, et al. Simvastatin impairs insulin secretion by multiple mechanisms in min6 cells. Plos One. 2015 2015/1/1;10(11):e142902.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1371/journal.pone.0142902</pub-id><pub-id pub-id-type="pmcid">PMC4641640</pub-id><pub-id pub-id-type="pmid">26561346</pub-id></mixed-citation></ref><ref id="b0100"><label>20</label><element-citation id="h0100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adhyaru</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>T.A.</given-names></name></person-group><article-title>Safety and efficacy of statin therapy</article-title><source>Nat Rev Cardiol</source><volume>15</volume><issue>12</issue><year>2018</year><fpage>757</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">30375494</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41569-018-0098-5</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation id="h0105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganga</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Slim</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P.D.</given-names></name></person-group><article-title>A systematic review of statin-induced muscle problems in clinical trials</article-title><source>Am Heart J</source><volume>168</volume><issue>1</issue><year>2014</year><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">24952854</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ahj.2014.03.019</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation id="h0110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Surapaneni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dunning</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Inker</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Association of rosuvastatin use with risk of hematuria and proteinuria</article-title><source>J Am Soc Nephrol</source><volume>33</volume><issue>9</issue><year>2022</year><fpage>1767</fpage><lpage>1777</lpage><pub-id pub-id-type="pmid">35853713</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1681/ASN.2022020135</pub-id><pub-id pub-id-type="pmcid">PMC9529194</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation id="h0115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases</article-title><source>Cardiovasc Diabetol</source><year>2022</year><comment>2022 May 23;21(1):82</comment><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s12933-022-01524-6</pub-id><pub-id pub-id-type="pmcid">PMC9128291</pub-id><pub-id pub-id-type="pmid">35606846</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation id="h0120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yokoya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Waguri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>J.</given-names></name></person-group><article-title>Rab-small gtpases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers</article-title><source>Faseb J</source><volume>21</volume><issue>14</issue><year>2007</year><fpage>4087</fpage><lpage>4094</lpage><pub-id pub-id-type="pmid">17634390</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1096/fj.07-8713com</pub-id></element-citation></ref><ref id="b0125"><label>25</label><mixed-citation id="h0125" publication-type="other">Ronzier E, Parks XX, Qudsi H, Lopes CM. Statin-specific inhibition of rab-gtpase regulates cpkc-mediated iks internalization. Sci Rep. 2019 2019 Nov 28;9(1):17747.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41598-019-53700-6</pub-id><pub-id pub-id-type="pmcid">PMC6882895</pub-id><pub-id pub-id-type="pmid">31780674</pub-id></mixed-citation></ref><ref id="b0130"><label>26</label><element-citation id="h0130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teramoto</surname><given-names>T.</given-names></name></person-group><article-title>Pitavastatin: clinical effects from the lives study</article-title><source>Atheroscler Suppl</source><volume>12</volume><issue>3</issue><year>2011</year><fpage>285</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">22152283</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S1567-5688(11)70888-1</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation id="h0135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taguchi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Iimuro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amiya</surname><given-names>E.</given-names></name><etal/></person-group><article-title>High-dose versus low-dose pitavastatin in japanese patients with stable coronary artery disease (real-cad): a randomized superiority trial</article-title><source>Circulation</source><volume>137</volume><issue>19</issue><year>2018</year><fpage>1997</fpage><lpage>2009</lpage><pub-id pub-id-type="pmid">29735587</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIRCULATIONAHA.117.032615</pub-id><pub-id pub-id-type="pmcid">PMC5959207</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation id="h0140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sirtori</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Corsini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Ruscica</surname><given-names>M.</given-names></name></person-group><article-title>Recent advances in synthetic pharmacotherapies for dyslipidaemias</article-title><source>Eur J Prev Cardiol</source><volume>27</volume><issue>15</issue><year>2020</year><fpage>1576</fpage><lpage>1596</lpage><pub-id pub-id-type="pmid">31060364</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/2047487319845314</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation id="h0145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.Y.</given-names></name><etal/></person-group><article-title>Effect of pitavastatin compared with atorvastatin androsuvastatin on new-onset diabetes mellitus in patientswith acute myocardial infarction</article-title><source>Am J Cardiol</source><volume>122</volume><issue>6</issue><year>2018</year><fpage>922</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">30217375</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.amjcard.2018.06.017</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation id="h0150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanke</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gomez-Mantilla</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stopfer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nock</surname><given-names>V.</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling of rosuvastatin to predict transporter-mediated drug-drug interactions</article-title><source>Pharm Res</source><volume>38</volume><issue>10</issue><year>2021</year><fpage>1645</fpage><lpage>1661</lpage><pub-id pub-id-type="pmid">34664206</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s11095-021-03109-6</pub-id><pub-id pub-id-type="pmcid">PMC8602162</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation id="h0155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>Effects of slco1b1 and gatm gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites</article-title><source>Acta Pharmacol Sin</source><volume>40</volume><issue>4</issue><year>2019</year><fpage>492</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">29950617</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41401-018-0013-y</pub-id><pub-id pub-id-type="pmcid">PMC6461793</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation id="h0160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercep</surname><given-names>I.</given-names></name><name name-style="western"><surname>Radman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Trkulja</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bozina</surname><given-names>T.</given-names></name><name name-style="western"><surname>Simicevic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Budimir</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Loss of function polymorphisms in slco1b1 (c.521t&gt;c, rs4149056) and abcg2 (c.421c&gt;a, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study</article-title><source>Eur J Clin Pharmacol</source><volume>78</volume><issue>2</issue><year>2022</year><fpage>227</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">34668025</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00228-021-03233-7</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation id="h0165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avins</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Manos</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ackerson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study</article-title><source>Drug Saf</source><year>2008</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.2165/00002018-200831040-00006</pub-id><pub-id pub-id-type="pmid">18366243</pub-id></element-citation></ref><ref id="b0170"><label>34</label><mixed-citation id="h0170" publication-type="other">Maroto-Martin C, Molina TP, Garcia PF. Atorvastatin-induced acute cholestatic hepatitis. Med Clin (Barc). 2022 2022 Dec 9;159(11):e77-78.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.medcli.2022.07.013</pub-id><pub-id pub-id-type="pmid">36030096</pub-id></mixed-citation></ref><ref id="b0175"><label>35</label><element-citation id="h0175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muldoon</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Barger</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Flory</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Lehoczky</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Effects of lovastatin on cognitive function and psychological well-being</article-title><source>Am J Med</source><volume>108</volume><issue>7</issue><year>2000</year><fpage>538</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">10806282</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0002-9343(00)00353-3</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation id="h0180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFarland</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Anoopkumar-Dukie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>A.V.</given-names></name><etal/></person-group><article-title>Molecular mechanisms underlying the effects of statins in the central nervous system</article-title><source>Int J Mol Sci</source><volume>15</volume><issue>11</issue><year>2014</year><fpage>20607</fpage><lpage>20637</lpage><pub-id pub-id-type="pmid">25391045</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/ijms151120607</pub-id><pub-id pub-id-type="pmcid">PMC4264186</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation id="h0185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binnington</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kamani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Budani</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Inhibition of rab prenylation by statins induces cellular glycosphingolipid remodeling</article-title><source>Glycobiology</source><volume>26</volume><issue>2</issue><year>2016</year><fpage>166</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">26405105</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/glycob/cwv084</pub-id><pub-id pub-id-type="pmcid">PMC4691287</pub-id></element-citation></ref><ref id="b0190"><label>38</label><mixed-citation id="h0190" publication-type="other">Preta G. Role of lactone and acid forms in the pleiotropic effects of statins. Pharmaceutics. 2022 2022 Sep 8;14(9).<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/pharmaceutics14091899</pub-id><pub-id pub-id-type="pmcid">PMC9503516</pub-id><pub-id pub-id-type="pmid">36145647</pub-id></mixed-citation></ref><ref id="b0195"><label>39</label><element-citation id="h0195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuerdi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anwaier</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice. Asian</article-title><source>J Pharm Sci</source><volume>15</volume><issue>1</issue><year>2020</year><fpage>112</fpage><lpage>120</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ajps.2019.02.002</pub-id><pub-id pub-id-type="pmcid">PMC7066038</pub-id><pub-id pub-id-type="pmid">32175023</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation id="h0200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pek</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tavintharan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Micrornas as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation</article-title><source>Exp Biol Med (Maywood)</source><volume>241</volume><issue>3</issue><year>2016</year><fpage>317</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">26429200</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/1535370215605588</pub-id><pub-id pub-id-type="pmcid">PMC4935448</pub-id></element-citation></ref><ref id="b0205"><label>41</label><mixed-citation id="h0205" publication-type="other">Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. Apoptotic injury in cultured human hepatocytes induced by hmg-coa reductase inhibitors. Biochem Pharmacol. 2004 2004 Jun 15;67(12):2175-86.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.bcp.2004.02.037</pub-id><pub-id pub-id-type="pmid">15163549</pub-id></mixed-citation></ref><ref id="b0210"><label>42</label><element-citation id="h0210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mihic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gaisano</surname><given-names>H.Y.</given-names></name><etal/></person-group><article-title>Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells</article-title><source>Endocrinology</source><volume>149</volume><issue>10</issue><year>2008</year><fpage>5136</fpage><lpage>5145</lpage><pub-id pub-id-type="pmid">18599549</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1210/en.2008-0161</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation id="h0215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Talati</surname><given-names>R.</given-names></name><name name-style="western"><surname>White</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C.I.</given-names></name></person-group><article-title>Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis</article-title><source>Diabetes Res Clin Pract</source><volume>87</volume><issue>1</issue><year>2010</year><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">19913318</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.diabres.2009.10.008</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation id="h0220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schultz</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Patten</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Berlau</surname><given-names>D.J.</given-names></name></person-group><article-title>The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms</article-title><source>Transl Neurodegener</source><volume>2018/1/1;7</volume><year>2018</year><fpage>5</fpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s40035-018-0110-3</pub-id><pub-id pub-id-type="pmcid">PMC5830056</pub-id><pub-id pub-id-type="pmid">29507718</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation id="h0225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Golomb</surname><given-names>B.A.</given-names></name></person-group><article-title>Statin-associated adverse cognitive effects: survey results from 171 patients</article-title><source>Pharmacotherapy</source><volume>29</volume><issue>7</issue><year>2009</year><fpage>800</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">19558254</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1592/phco.29.7.800</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation id="h0230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fulcher</surname><given-names>J.</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mihaylova</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Efficacy and safety of ldl-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials</article-title><source>Lancet</source><volume>385</volume><issue>9976</issue><year>2015</year><fpage>1397</fpage><lpage>1405</lpage><pub-id pub-id-type="pmid">25579834</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(14)61368-4</pub-id></element-citation></ref><ref id="b0235"><label>47</label><mixed-citation id="h0235" publication-type="other">Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019 2019 Feb 2;393(10170):407-15.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(18)31942-1</pub-id><pub-id pub-id-type="pmcid">PMC6429627</pub-id><pub-id pub-id-type="pmid">30712900</pub-id></mixed-citation></ref><ref id="b0240"><label>48</label><mixed-citation id="h0240" publication-type="other">Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. Nla scientific statement on statin intolerance: a new definition and key considerations for ascvd risk reduction in the statin intolerant patient. J Clin Lipidol. 2022 2022 Jul-Aug;16(4):361-75.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacl.2022.05.068</pub-id><pub-id pub-id-type="pmid">35718660</pub-id></mixed-citation></ref><ref id="b0245"><label>49</label><mixed-citation id="h0245" publication-type="other">Bytyci I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022 2022 Sep 7;43(34):3213-23.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/eurheartj/ehac015</pub-id><pub-id pub-id-type="pmcid">PMC9757867</pub-id><pub-id pub-id-type="pmid">35169843</pub-id></mixed-citation></ref><ref id="b0250"><label>50</label><mixed-citation id="h0250" publication-type="other">Thompson W, Morin L, Jarbol DE, Andersen JH, Ernst MT, Nielsen JB, et al. Statin discontinuation and cardiovascular events among older people in denmark. Jama Netw Open. 2021 2021 Dec 1;4(12):e2136802.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/jamanetworkopen.2021.36802</pub-id><pub-id pub-id-type="pmcid">PMC8640890</pub-id><pub-id pub-id-type="pmid">34854906</pub-id></mixed-citation></ref><ref id="b0255"><label>51</label><element-citation id="h0255" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Nordestgaard</surname><given-names>B.G.</given-names></name></person-group><article-title>Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study</article-title><source>Eur Heart J</source><volume>37</volume><issue>11</issue><year>2016</year><fpage>908</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">26643266</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/eurheartj/ehv641</pub-id></element-citation></ref><ref id="b0260"><label>52</label><mixed-citation id="h0260" publication-type="other">Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024 2024 May;12(5):306-19.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S2213-8587(24)00040-8</pub-id><pub-id pub-id-type="pmcid">PMC7615958</pub-id><pub-id pub-id-type="pmid">38554713</pub-id></mixed-citation></ref><ref id="b0265"><label>53</label><mixed-citation id="h0265" publication-type="other">Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007 2007 Jul 31;50(5):409-18.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacc.2007.02.073</pub-id><pub-id pub-id-type="pmid">17662392</pub-id></mixed-citation></ref><ref id="b0270"><label>54</label><element-citation id="h0270" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Langford</surname><given-names>O.</given-names></name><name name-style="western"><surname>Monaghan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aronson</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses</article-title><source>BMJ</source><volume>14</volume><issue>374</issue><year>2021</year><object-id pub-id-type="publisher-id">n1537</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/bmj.n1537</pub-id><pub-id pub-id-type="pmcid">PMC8279037</pub-id><pub-id pub-id-type="pmid">34261627</pub-id></element-citation></ref><ref id="b0275"><label>55</label><mixed-citation id="h0275" publication-type="other">Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019 2019 Jan 18;124(2):328-50.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIRCRESAHA.118.312782</pub-id><pub-id pub-id-type="pmid">30653440</pub-id></mixed-citation></ref><ref id="b0280"><label>56</label><mixed-citation id="h0280" publication-type="other">Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The NLAM. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014 2014 May-Jun;8(3 Suppl):S58-71.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacl.2014.03.004</pub-id><pub-id pub-id-type="pmid">24793443</pub-id></mixed-citation></ref><ref id="b0285"><label>57</label><mixed-citation id="h0285" publication-type="other">Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021 2021 Oct 28;22(21).<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/ijms222111687</pub-id><pub-id pub-id-type="pmcid">PMC8583847</pub-id><pub-id pub-id-type="pmid">34769118</pub-id></mixed-citation></ref><ref id="b0290"><label>58</label><element-citation id="h0290" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruckert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hayem</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dejager</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Begaud</surname><given-names>B.</given-names></name></person-group><source>Cardiovasc Drugs Ther</source><volume>19</volume><issue>6</issue><year>2005 2005 Dec,</year><fpage>403</fpage><lpage>414</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10557-005-5686-z</pub-id><pub-id pub-id-type="pmid">16453090</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation id="h0295" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirota</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I.</given-names></name></person-group><article-title>An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins</article-title><source>Expert Opin Drug Metab Toxicol</source><volume>16</volume><issue>9</issue><year>2020 2020 Sep,</year><fpage>809</fpage><lpage>822</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/17425255.2020.1801634</pub-id><pub-id pub-id-type="pmid">32729746</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation id="h0300" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balasubramanian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maideen</surname><given-names>N.</given-names></name></person-group><article-title>Hmg-coa reductase inhibitors (statins) and their drug interactions involving cyp enzymes, p-glycoprotein and oatp transporters-an overview</article-title><source>Curr Drug Metab</source><year>2021</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.2174/1389200222666210114122729</pub-id><pub-id pub-id-type="pmid">33459228</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation id="h0305" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ares</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Martinez-Larranaga</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Statins: adverse reactions, oxidative stress and metabolic interactions</article-title><source>Pharmacol Ther</source><volume>2019</volume><issue>195</issue><year>2019</year><fpage>54</fpage><lpage>84</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.pharmthera.2018.10.004</pub-id><pub-id pub-id-type="pmid">30321555</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation id="h0310" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Disease status-dependent drug-herb interactions: nash lowered the risk of hepatotoxicity in rats coadministered with simvastatin and gardenia jasminoides j</article-title><source>Ellis Front Pharmacol</source><year>2021</year><object-id pub-id-type="publisher-id">2021/1/1;12:622040</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fphar.2021.622040</pub-id><pub-id pub-id-type="pmcid">PMC8103205</pub-id><pub-id pub-id-type="pmid">33967756</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation id="h0315" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azemawah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Movahed</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Centuori</surname><given-names>P.</given-names></name><name name-style="western"><surname>Penaflor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riel</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Situ</surname><given-names>S.</given-names></name><etal/></person-group><article-title>State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications</article-title><source>Cardiovasc Drugs Ther</source><volume>33</volume><issue>5</issue><year>2019</year><fpage>625</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">31773344</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10557-019-06904-x</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation id="h0320" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lilja</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kivisto</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>P.J.</given-names></name></person-group><article-title>Duration of effect of grapefruit juice on the pharmacokinetics of the cyp3a4 substrate simvastatin</article-title><source>Clin Pharmacol Ther</source><volume>68</volume><issue>4</issue><year>2000</year><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">11061578</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1067/mcp.2000.110216</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation id="h0325" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zechner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Britza</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Farrington</surname><given-names>R.</given-names></name><name name-style="western"><surname>Byard</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Musgrave</surname><given-names>I.F.</given-names></name></person-group><article-title>Flavonoid-statin interactions causing myopathy and the possible significance of oatp transport, cyp450 metabolism and mevalonate synthesis</article-title><source>Life Sci</source><volume>15</volume><issue>291</issue><year>2022</year><object-id pub-id-type="publisher-id">119975</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.lfs.2021.119975</pub-id><pub-id pub-id-type="pmid">34560084</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation id="h0330" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ellington</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zdrojewski</surname><given-names>I.</given-names></name><name name-style="western"><surname>Parent</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily</article-title><source>Br J Clin Pharmacol</source><volume>72</volume><issue>3</issue><year>2011</year><fpage>434</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">21501216</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/j.1365-2125.2011.03996.x</pub-id><pub-id pub-id-type="pmcid">PMC3175512</pub-id></element-citation></ref><ref id="b0335"><label>67</label><mixed-citation id="h0335" publication-type="other">Awad K, Serban MC, Penson P, Mikhailidis DP, Toth PP, Jones SR, et al. Effects of morning vs evening statin administration on lipid profile: a systematic review and meta-analysis. J Clin Lipidol. 2017 2017 Jul-Aug;11(4):972-85.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacl.2017.06.001</pub-id><pub-id pub-id-type="pmid">28826569</pub-id></mixed-citation></ref><ref id="b0340"><label>68</label><mixed-citation id="h0340" publication-type="other">Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2023 2023 Jan 18;118(17):3288-304.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/cvr/cvac020</pub-id><pub-id pub-id-type="pmid">35238338</pub-id></mixed-citation></ref><ref id="b0345"><label>69</label><element-citation id="h0345" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tomlinson</surname><given-names>B.</given-names></name></person-group><article-title>Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin</article-title><source>Expert Opin Drug Metab Toxicol</source><volume>10</volume><issue>1</issue><year>2014</year><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">24156555</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1517/17425255.2014.851667</pub-id></element-citation></ref><ref id="b0350"><label>70</label><element-citation id="h0350" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tomlinson</surname><given-names>B.</given-names></name></person-group><article-title>Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation</article-title><source>Expert Opin Drug Saf</source><volume>2024</volume><issue>3</issue><year>2024</year><fpage>1</fpage><lpage>08</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/14740338.2024.2424411</pub-id><pub-id pub-id-type="pmid">39485240</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation id="h0355" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damiani</surname><given-names>I.</given-names></name><name name-style="western"><surname>Corsini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bellosta</surname><given-names>S.</given-names></name></person-group><article-title>Potential statin drug interactions in elderly patients: a review</article-title><source>Expert Opin Drug Metab Toxicol</source><volume>16</volume><issue>12</issue><year>2020</year><fpage>1133</fpage><lpage>1145</lpage><pub-id pub-id-type="pmid">32909838</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/17425255.2020.1822324</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation id="h0360" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dube</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Zetler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barhdadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Mongrain</surname><given-names>I.</given-names></name><name name-style="western"><surname>Normand</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Ckm and lilrb5 are associated with serum levels of creatine kinase</article-title><source>Circ Cardiovasc Genet</source><volume>7</volume><issue>6</issue><year>2014</year><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">25214527</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIRCGENETICS.113.000395</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation id="h0365" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristjansson</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Oddsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Helgason</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sveinbjornsson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arnadottir</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Jensson</surname><given-names>B.O.</given-names></name><etal/></person-group><article-title>Common and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase</article-title><source>Nat Commun</source><volume>3</volume><issue>7</issue><year>2016</year><fpage>10572</fpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ncomms10572</pub-id><pub-id pub-id-type="pmcid">PMC4742860</pub-id><pub-id pub-id-type="pmid">26838040</pub-id></element-citation></ref><ref id="b0370"><label>74</label><mixed-citation id="h0370" publication-type="other">K SM, Maroteau C, Veluchamy A, Tornio A, Tavendale R, Carr F, et al. A common missense variant of lilrb5 is associated with statin intolerance and myalgia. Eur Heart J. 2017 2017 Dec 21;38(48):3569-75.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/eurheartj/ehx467</pub-id><pub-id pub-id-type="pmcid">PMC5837247</pub-id><pub-id pub-id-type="pmid">29020356</pub-id></mixed-citation></ref><ref id="b0375"><label>75</label><mixed-citation id="h0375" publication-type="other">Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. Role of oatp1b1 and oatp1b3 in drug-drug interactions mediated by tyrosine kinase inhibitors. Pharmaceutics. 2020 2020 Sep 9;12(9).<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/pharmaceutics12090856</pub-id><pub-id pub-id-type="pmcid">PMC7559291</pub-id><pub-id pub-id-type="pmid">32916864</pub-id></mixed-citation></ref><ref id="b0380"><label>76</label><element-citation id="h0380" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klaassen</surname><given-names>C.D.</given-names></name></person-group><article-title>Elucidation of oatp1b1 and 1b3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms</article-title><source>Toxicol Appl Pharmacol</source><volume>15</volume><issue>399</issue><year>2020</year><object-id pub-id-type="publisher-id">115039</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.taap.2020.115039</pub-id><pub-id pub-id-type="pmid">32407928</pub-id></element-citation></ref><ref id="b0385"><label>77</label><element-citation id="h0385" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linskey</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>English</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Ochs-Balcom</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Isackson</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Association of slco1b1 c.521t&gt;c (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms</article-title><source>Pharmacogenet Genomics</source><volume>30</volume><issue>9</issue><year>2020</year><fpage>208</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">32453264</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/FPC.0000000000000412</pub-id><pub-id pub-id-type="pmcid">PMC8062056</pub-id></element-citation></ref><ref id="b0390"><label>78</label><element-citation id="h0390" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilke</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Maxwell</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Voora</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The clinical pharmacogenomics implementation consortium: cpic guideline for slco1b1 and simvastatin-induced myopathy</article-title><source>Clin Pharmacol Ther</source><volume>92</volume><issue>1</issue><year>2012</year><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">22617227</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/clpt.2012.57</pub-id><pub-id pub-id-type="pmcid">PMC3384438</pub-id></element-citation></ref><ref id="b0395"><label>79</label><mixed-citation id="h0395" publication-type="other">Dagli-Hernandez C, de Freitas R, Marcal E, Goncalves RM, Faludi AA, Borges JB, et al. Late response to rosuvastatin and statin-related myalgia due to slco1b1, slco1b3, abcb11, and cyp3a5 variants in a patient with familial hypercholesterolemia: a case report. Ann Transl Med. 2021 2021 Jan;9(1):76.<pub-id assigning-authority="pmc" pub-id-type="doi">10.21037/atm-20-5540</pub-id><pub-id pub-id-type="pmcid">PMC7859822</pub-id><pub-id pub-id-type="pmid">33553369</pub-id></mixed-citation></ref><ref id="b0400"><label>80</label><element-citation id="h0400" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leil</surname><given-names>T.</given-names></name></person-group><article-title>Investigating transporter-mediated drug-drug interactions using a physiologically based pharmacokinetic model of rosuvastatin</article-title><source>Cpt Pharmacometrics Syst Pharmacol</source><volume>6</volume><issue>4</issue><year>2017</year><fpage>228</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">28296193</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/psp4.12168</pub-id><pub-id pub-id-type="pmcid">PMC5397561</pub-id></element-citation></ref><ref id="b0405"><label>81</label><element-citation id="h0405" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kee</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Maggo</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacogenetics of statin-induced myotoxicity</article-title><source>Front Genet</source><year>2020</year><object-id pub-id-type="publisher-id">2020/1/1;11:575678</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fgene.2020.575678</pub-id><pub-id pub-id-type="pmcid">PMC7596698</pub-id><pub-id pub-id-type="pmid">33193687</pub-id></element-citation></ref><ref id="b0410"><label>82</label><mixed-citation id="h0410" publication-type="other">Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A statin-dependent qtl for gatm expression is associated with statin-induced myopathy. Nature. 2013 2013 Oct 17;502(7471):377-80.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/nature12508</pub-id><pub-id pub-id-type="pmcid">PMC3933266</pub-id><pub-id pub-id-type="pmid">23995691</pub-id></mixed-citation></ref><ref id="b0415"><label>83</label><element-citation id="h0415" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>The association of gatm polymorphism with statin-induced myopathy: a systematic review and meta-analysis</article-title><source>Eur J Clin Pharmacol</source><volume>77</volume><issue>3</issue><year>2021</year><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">33051696</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00228-020-03019-3</pub-id><pub-id pub-id-type="pmcid">PMC7867530</pub-id></element-citation></ref><ref id="b0420"><label>84</label><mixed-citation id="h0420" publication-type="other">Carr DF, Alfirevic A, Johnson R, Chinoy H, van Staa T, Pirmohamed M. Gatm gene variants and statin myopathy risk. Nature. 2014 2014 Sep 18;513(7518):E1.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/nature13628</pub-id><pub-id pub-id-type="pmid">25230669</pub-id></mixed-citation></ref><ref id="b0425"><label>85</label><element-citation id="h0425" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greene</surname><given-names>J.</given-names></name><name name-style="western"><surname>Segaran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>S.</given-names></name></person-group><article-title>Targeting oxphos and the electron transport chain in cancer; Molecular and therapeutic implications</article-title><source>Semin Cancer Biol</source><volume>86</volume><issue>Pt 2</issue><year>2022</year><fpage>851</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">35122973</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.semcancer.2022.02.002</pub-id></element-citation></ref><ref id="b0430"><label>86</label><mixed-citation id="h0430" publication-type="other">Ahmad M, Wolberg A, Kahwaji CI. Biochemistry, electron transport chain. 2023 2023 Jan.<pub-id pub-id-type="pmid">30252361</pub-id></mixed-citation></ref><ref id="b0435"><label>87</label><mixed-citation id="h0435" publication-type="other">Mantle D, Millichap L, Castro-Marrero J, Hargreaves IP. Primary coenzyme q10 deficiency: an update. Antioxidants (Basel). 2023 2023 Aug 21;12(8).<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/antiox12081652</pub-id><pub-id pub-id-type="pmcid">PMC10451954</pub-id><pub-id pub-id-type="pmid">37627647</pub-id></mixed-citation></ref><ref id="b0440"><label>88</label><mixed-citation id="h0440" publication-type="other">Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of coenzyme q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018 2018 Oct 2;7(19):e9835.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/JAHA.118.009835</pub-id><pub-id pub-id-type="pmcid">PMC6404871</pub-id><pub-id pub-id-type="pmid">30371340</pub-id></mixed-citation></ref><ref id="b0445"><label>89</label><element-citation id="h0445" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Whayne</surname><given-names>T.J.</given-names></name></person-group><article-title>Coenzyme q-10 in human health: supporting evidence?</article-title><source>South Med J</source><volume>109</volume><issue>1</issue><year>2016</year><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">26741866</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.14423/SMJ.0000000000000393</pub-id></element-citation></ref><ref id="b0450"><label>90</label><element-citation id="h0450" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vladutiu</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Isackson</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Tarnopolsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peltier</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Barboi</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Genetic risk factors associated with lipid-lowering drug-induced myopathies</article-title><source>Muscle Nerve</source><volume>34</volume><issue>2</issue><year>2006</year><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">16671104</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/mus.20567</pub-id></element-citation></ref><ref id="b0455"><label>91</label><element-citation id="h0455" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hur</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Laaksonen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.P.</given-names></name></person-group><article-title>Drug-induced rhabdomyolysis: from systems pharmacology analysis to biochemical flux</article-title><source>Chem Res Toxicol</source><volume>27</volume><issue>3</issue><year>2014</year><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">24422454</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1021/tx400409c</pub-id></element-citation></ref><ref id="b0460"><label>92</label><mixed-citation id="h0460" publication-type="other">Dohlmann TL, Kuhlman AB, Morville T, Dahl M, Asping M, Orlando P, et al. Coenzyme q10 supplementation in statin treated patients: a double-blinded randomized placebo-controlled trial. Antioxidants (Basel). 2022 2022 Aug 29;11(9).<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/antiox11091698</pub-id><pub-id pub-id-type="pmcid">PMC9495827</pub-id><pub-id pub-id-type="pmid">36139772</pub-id></mixed-citation></ref><ref id="b0465"><label>93</label><element-citation id="h0465" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ochs-Balcom</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Isackson</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Vladutiu</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Luzum</surname><given-names>J.A.</given-names></name></person-group><article-title>Coenzyme q10 supplementation for the treatment of statin-associated muscle symptoms</article-title><source>Future Cardiol</source><volume>18</volume><issue>6</issue><year>2022</year><fpage>461</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">35297269</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.2217/fca-2021-0106</pub-id><pub-id pub-id-type="pmcid">PMC9171566</pub-id></element-citation></ref><ref id="b0470"><label>94</label><mixed-citation id="h0470" publication-type="other">Hargreaves I, Heaton RA, Mantle D. Disorders of human coenzyme q10 metabolism: an overview. Int J Mol Sci. 2020 2020 Sep 13;21(18).<pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/ijms21186695</pub-id><pub-id pub-id-type="pmcid">PMC7555759</pub-id><pub-id pub-id-type="pmid">32933108</pub-id></mixed-citation></ref><ref id="b0475"><label>95</label><element-citation id="h0475" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deshwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tatsuta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cors</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ried</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Mitochondria regulate intracellular coenzyme q transport and ferroptotic resistance via stard7</article-title><source>Nat Cell Biol</source><volume>25</volume><issue>2</issue><year>2023</year><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">36658222</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41556-022-01071-y</pub-id><pub-id pub-id-type="pmcid">PMC9928583</pub-id></element-citation></ref><ref id="b0480"><label>96</label><element-citation id="h0480" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finck</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.P.</given-names></name></person-group><article-title>Pgc-1 coactivators: inducible regulators of energy metabolism in health and disease</article-title><source>J Clin Invest</source><volume>116</volume><issue>3</issue><year>2006</year><fpage>615</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">16511594</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1172/JCI27794</pub-id><pub-id pub-id-type="pmcid">PMC1386111</pub-id></element-citation></ref><ref id="b0485"><label>97</label><mixed-citation id="h0485" publication-type="other">Panajatovic M, Singh F, Duthaler U, Krahenbuhl S, Bouitbir J. Role of pgc-1-alpha-associated mitochondrial biogenesis in statin-induced myotoxicity. Eur Cardiol. 2020 2020 Feb;15:e35.<pub-id assigning-authority="pmc" pub-id-type="doi">10.15420/ecr.2020.15.1.PO12</pub-id><pub-id pub-id-type="pmcid">PMC7312613</pub-id><pub-id pub-id-type="pmid">32612695</pub-id></mixed-citation></ref><ref id="b0490"><label>98</label><element-citation id="h0490" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mermier</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Bisoffi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trujillo</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Conn</surname><given-names>C.A.</given-names></name></person-group><article-title>Dietary stimulators of the pgc-1 superfamily and mitochondrial biosynthesis in skeletal muscle. A mini-review</article-title><source>J Physiol Biochem</source><volume>70</volume><issue>1</issue><year>2014</year><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">24338337</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s13105-013-0301-4</pub-id></element-citation></ref><ref id="b0495"><label>99</label><element-citation id="h0495" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zoll</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duthaler</surname><given-names>U.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Panajatovic</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Laverny</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Pgc-1beta modulates statin-associated myotoxicity in mice</article-title><source>Arch Toxicol</source><volume>93</volume><issue>2</issue><year>2019</year><fpage>487</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">30511338</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00204-018-2369-7</pub-id></element-citation></ref><ref id="b0500"><label>100</label><element-citation id="h0500" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Luciano</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Pauli</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Caperuto</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Treadmill training increases sirt-1 and pgc-1 alpha protein levels and ampk phosphorylation in quadriceps of middle-aged rats in an intensity-dependent manner</article-title><source>Mediators Inflamm</source><year>2014</year><object-id pub-id-type="publisher-id">2014/1/1;2014:987017</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1155/2014/987017</pub-id><pub-id pub-id-type="pmcid">PMC4070581</pub-id><pub-id pub-id-type="pmid">25002755</pub-id><related-article ext-link-type="pmc" related-article-type="retraction-forward" xlink:href="PMC5662800" xmlns:xlink="http://www.w3.org/1999/xlink"/></element-citation></ref><ref id="b0505"><label>101</label><element-citation id="h0505" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name></person-group><article-title>Mammalian akt, the emerging roles on mitochondrial function in diseases</article-title><source>Aging Dis</source><volume>13</volume><issue>1</issue><year>2022</year><fpage>157</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">35111368</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.14336/AD.2021.0729</pub-id><pub-id pub-id-type="pmcid">PMC8782557</pub-id></element-citation></ref><ref id="b0510"><label>102</label><element-citation id="h0510" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonifacio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanvee</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Brecht</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kratschmar</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Odermatt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouitbir</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Igf-1 prevents simvastatin-induced myotoxicity in c2c12 myotubes</article-title><source>Arch Toxicol</source><volume>91</volume><issue>5</issue><year>2017</year><fpage>2223</fpage><lpage>2234</lpage><pub-id pub-id-type="pmid">27734117</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00204-016-1871-z</pub-id></element-citation></ref><ref id="b0515"><label>103</label><element-citation id="h0515" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camerino</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>De Bellis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conte</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liantonio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Musaraj</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cannone</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Statin-induced myotoxicity is exacerbated by aging: a biophysical and molecular biology study in rats treated with atorvastatin</article-title><source>Toxicol Appl Pharmacol</source><volume>1</volume><issue>306</issue><year>2016</year><fpage>36</fpage><lpage>46</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.taap.2016.06.032</pub-id><pub-id pub-id-type="pmid">27377005</pub-id></element-citation></ref><ref id="b0520"><label>104</label><element-citation id="h0520" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dietary geranylgeranyl pyrophosphate counteracts the benefits of statin therapy in experimental pulmonary hypertension</article-title><source>Circulation</source><volume>143</volume><issue>18</issue><year>2021</year><fpage>1775</fpage><lpage>1792</lpage><pub-id pub-id-type="pmid">33660517</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046542</pub-id></element-citation></ref><ref id="b0525"><label>105</label><mixed-citation id="h0525" publication-type="other">Huai J, Yang Z, Yi YH, Wang GJ. [Changes of rheb gene and protein expression in preeclampsia-like mouse model treated with pravastatin]. Zhonghua Fu Chan Ke Za Zhi. 2019 2019 Jan 25;54(1):38-43.<pub-id assigning-authority="pmc" pub-id-type="doi">10.3760/cma.j.issn.0529-567x.2019.01.009</pub-id><pub-id pub-id-type="pmid">30695905</pub-id></mixed-citation></ref><ref id="b0530"><label>106</label><mixed-citation id="h0530" publication-type="other">Waldeck-Weiermair M, Yadav S, Kaynert J, Thulabandu VR, Pandey AK, Spyropoulos F, et al. Differential endothelial hydrogen peroxide signaling via nox isoforms: critical roles for rac1 and modulation by statins. Redox Biol. 2022 2022 Dec;58:102539.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.redox.2022.102539</pub-id><pub-id pub-id-type="pmcid">PMC9673117</pub-id><pub-id pub-id-type="pmid">36401888</pub-id></mixed-citation></ref><ref id="b0535"><label>107</label><element-citation id="h0535" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warden</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Guyton</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Durham</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Assessment and management of statin-associated muscle symptoms (sams): a clinical perspective from the national lipid association</article-title><source>J Clin Lipidol</source><year>2023</year><comment>2023 Jan-Feb;17(1):19–39</comment><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacl.2022.09.001</pub-id><pub-id pub-id-type="pmid">36115813</pub-id></element-citation></ref><ref id="b0540"><label>108</label><element-citation id="h0540" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavilan-Carrera</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soriano-Maldonado</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mediavilla-Garcia</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Lavie</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Vargas-Hitos</surname><given-names>J.A.</given-names></name></person-group><article-title>Prescribing statin therapy in physically (in)active individuals vs prescribing physical activity in statin-treated patients: a four-scenario practical approach</article-title><source>Pharmacol Res</source><volume>197</volume><year>2023</year><object-id pub-id-type="publisher-id">106962</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.phrs.2023.106962</pub-id><pub-id pub-id-type="pmid">37866703</pub-id></element-citation></ref><ref id="b0545"><label>109</label><element-citation id="h0545" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bayliss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Baccara-Dinet</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Chibedi-De-Roche</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The statin-associated muscle symptom clinical index (sams-ci): revision for clinical use, content validation, and inter-rater reliability</article-title><source>Cardiovasc Drugs Ther</source><volume>31</volume><issue>2</issue><year>2017</year><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">28421332</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10557-017-6723-4</pub-id><pub-id pub-id-type="pmcid">PMC5427100</pub-id></element-citation></ref><ref id="b0550"><label>110</label><mixed-citation id="h0550" publication-type="other">Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (racing): a randomised, open-label, non-inferiority trial. Lancet. 2022 2022 Jul 30;400(10349):380-90.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(22)00916-3</pub-id><pub-id pub-id-type="pmid">35863366</pub-id></mixed-citation></ref><ref id="b0555"><label>111</label><element-citation id="h0555" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nissen</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Lincoff</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kastelein</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Bempedoic acid and cardiovascular outcomes in statin-intolerant patients</article-title><source>N Engl J Med</source><volume>388</volume><issue>15</issue><year>2023</year><fpage>1353</fpage><lpage>1364</lpage><pub-id pub-id-type="pmid">36876740</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa2215024</pub-id></element-citation></ref><ref id="b0560"><label>112</label><element-citation id="h0560" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Raal</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Kallend</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Jaros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis</article-title><source>J Am Coll Cardiol</source><volume>77</volume><issue>9</issue><year>2021 2021 Mar 9,</year><fpage>1182</fpage><lpage>1193</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacc.2020.12.058</pub-id><pub-id pub-id-type="pmid">33663735</pub-id></element-citation></ref><ref id="b0565"><label>113</label><mixed-citation id="h0565" publication-type="other">Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein J, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020 2020 Aug 20;383(8):711-20.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa2004215</pub-id><pub-id pub-id-type="pmid">32813947</pub-id></mixed-citation></ref><ref id="b0570"><label>114</label><mixed-citation id="h0570" publication-type="other">Abdul-Rahman T, Bukhari S, Herrera EC, Awuah WA, Lawrence J, de Andrade H, et al. Lipid lowering therapy: an era beyond statins. Curr Probl Cardiol. 2022 2022 Dec;47(12):101342.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cpcardiol.2022.101342</pub-id><pub-id pub-id-type="pmid">35918009</pub-id></mixed-citation></ref><ref id="b0575"><label>115</label><mixed-citation id="h0575" publication-type="other">Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights. Drug Des Devel Ther. 2022 2022/1/1;16:2177-86.<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/DDDT.S332352</pub-id><pub-id pub-id-type="pmcid">PMC9273150</pub-id><pub-id pub-id-type="pmid">35832642</pub-id></mixed-citation></ref><ref id="b0580"><label>116</label><element-citation id="h0580" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mikhailidis</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Moriarty</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lip</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis</article-title><source>Cardiovasc Drugs Ther</source><volume>31</volume><issue>4</issue><year>2017</year><fpage>419</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">28741244</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10557-017-6743-0</pub-id></element-citation></ref><ref id="b0585"><label>117</label><element-citation id="h0585" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruscica</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sirtori</surname><given-names>C.R.</given-names></name></person-group><article-title>Can we further optimize statin therapy to increase tolerability?</article-title><source>Expert Opin Drug Discov</source><volume>14</volume><issue>9</issue><year>2019</year><fpage>843</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">31096808</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/17460441.2019.1615436</pub-id></element-citation></ref><ref id="b0590"><label>118</label><element-citation id="h0590" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Wat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C.S.</given-names></name><etal/></person-group><article-title>Effect of green tea extract and soy isoflavones on the pharmacokinetics of rosuvastatin in healthy volunteers</article-title><source>Front Nutr</source><volume>2022/1/1;9</volume><year>2022</year><object-id pub-id-type="publisher-id">850318</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fnut.2022.850318</pub-id><pub-id pub-id-type="pmcid">PMC8987933</pub-id><pub-id pub-id-type="pmid">35399656</pub-id></element-citation></ref><ref id="b0595"><label>119</label><element-citation id="h0595" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Wat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C.S.</given-names></name><etal/></person-group><article-title>Effects of soy isoflavones and green tea extract on simvastatin pharmacokinetics and influence of the slco1b1 521t &gt; c polymorphism</article-title><source>Front Nutr</source><volume>2022/1/1;9</volume><year>2022</year><object-id pub-id-type="publisher-id">868126</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fnut.2022.868126</pub-id><pub-id pub-id-type="pmcid">PMC9171976</pub-id><pub-id pub-id-type="pmid">35685887</pub-id></element-citation></ref><ref id="b0600"><label>120</label><mixed-citation id="h0600" publication-type="other">Banach M, Patti AM, Giglio RV, Cicero A, Atanasov AG, Bajraktari G, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018 2018 Jul 3;72(1):96-118.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacc.2018.04.040</pub-id><pub-id pub-id-type="pmid">29957236</pub-id></mixed-citation></ref><ref id="b0605"><label>121</label><element-citation id="h0605" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollazadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tavana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fanni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banach</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pirro</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effects of statins on mitochondrial pathways</article-title><source>J Cachexia Sarcopenia Muscle</source><volume>12</volume><issue>2</issue><year>2021</year><fpage>237</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">33511728</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/jcsm.12654</pub-id><pub-id pub-id-type="pmcid">PMC8061391</pub-id></element-citation></ref><ref id="b0610"><label>122</label><element-citation id="h0610" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teutonico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Libutti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lomonte</surname><given-names>C.</given-names></name><name name-style="western"><surname>Basile</surname><given-names>C.</given-names></name></person-group><article-title>Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis</article-title><source>NDT Plus</source><volume>3</volume><issue>3</issue><year>2010</year><fpage>273</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">28657046</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/ndtplus/sfq012</pub-id><pub-id pub-id-type="pmcid">PMC5477947</pub-id></element-citation></ref><ref id="b0615"><label>123</label><element-citation id="h0615" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petreski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Petrijan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dvorsak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hojs</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bevc</surname><given-names>S.</given-names></name></person-group><article-title>Statin-associated necrotizing myopathy leading to acute kidney injury: a case report</article-title><source>Case Rep Nephrol Dial</source><year>2021</year><comment>2021 May-Aug;11(2):129–35</comment><pub-id assigning-authority="pmc" pub-id-type="doi">10.1159/000515584</pub-id><pub-id pub-id-type="pmcid">PMC8255745</pub-id><pub-id pub-id-type="pmid">34250030</pub-id></element-citation></ref><ref id="b0620"><label>124</label><element-citation id="h0620" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chockalingam</surname><given-names>A.</given-names></name></person-group><article-title>Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic nstemi: a review of lipid management considerations</article-title><source>Am J Ther</source><volume>20</volume><issue>1</issue><year>2013</year><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">21192242</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MJT.0b013e3181ff7c79</pub-id></element-citation></ref><ref id="b0625"><label>125</label><mixed-citation id="h0625" publication-type="other">Medina-Romero J, Toledo-Salinas O, Reyes-Alvarez FJ, Gomez-Flores SS. [Severe rhabdomyolysis associated with atorvastatin. Case report]. Rev Med Inst Mex Seguro Soc. 2023 2023 Mar 1;61(2):245-50.<pub-id pub-id-type="pmcid">PMC10395881</pub-id><pub-id pub-id-type="pmid">37207311</pub-id></mixed-citation></ref><ref id="b0630"><label>126</label><element-citation id="h0630" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frydrychowicz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pasieka</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pierer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>W.</given-names></name><name name-style="western"><surname>Petros</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weidhase</surname><given-names>L.</given-names></name></person-group><article-title>Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report</article-title><source>J Med Case Rep</source><year>2017</year><comment>2017 Jan 4;11(1):8</comment><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s13256-016-1169-z</pub-id><pub-id pub-id-type="pmcid">PMC5209950</pub-id><pub-id pub-id-type="pmid">28049514</pub-id></element-citation></ref><ref id="b0635"><label>127</label><element-citation id="h0635" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yebyo</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Aschmann</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Puhan</surname><given-names>M.A.</given-names></name></person-group><article-title>Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants</article-title><source>Am Heart J</source><volume>2019</volume><issue>210</issue><year>2019</year><fpage>18</fpage><lpage>28</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ahj.2018.12.007</pub-id><pub-id pub-id-type="pmid">30716508</pub-id></element-citation></ref><ref id="b0640"><label>128</label><element-citation id="h0640" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graff</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Signoretti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>M.A.</given-names></name></person-group><article-title>Statin use and risk of renal cell carcinoma in three prospective cohort studies</article-title><source>J Clin Oncol</source><volume>36(6_suppl):679</volume><year>2018</year></element-citation></ref><ref id="b0645"><label>129</label><mixed-citation id="h0645" publication-type="other">Masson W, Lobo M, Masson G, Molinero G, Casciato P. Statin use in patients with elevated serum hepatic transaminases at baseline: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021 2021 May 6;31(5):1357-64.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.numecd.2021.01.026</pub-id><pub-id pub-id-type="pmid">33715945</pub-id></mixed-citation></ref><ref id="b0650"><label>130</label><mixed-citation id="h0650" publication-type="other">Barkas F, Adamidis P, Koutsogianni AD, Liamis G, Liberopoulos E. Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study. Arch Med Sci Atheroscler Dis. 2021 2021/1/1;6:e182-87.<pub-id assigning-authority="pmc" pub-id-type="doi">10.5114/amsad.2021.111313</pub-id><pub-id pub-id-type="pmcid">PMC9487797</pub-id><pub-id pub-id-type="pmid">36161219</pub-id></mixed-citation></ref><ref id="b0655"><label>131</label><mixed-citation id="h0655" publication-type="other">Karahalil B, Hare E, Koc G, Uslu I, Senturk K, Ozkan Y. Hepatotoxicity associated with statins. Arh Hig Rada Toksikol. 2017 2017 Dec 20;68(4):254-60.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1515/aiht-2017-68-2994</pub-id><pub-id pub-id-type="pmid">29337684</pub-id></mixed-citation></ref><ref id="b0660"><label>132</label><element-citation id="h0660" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gitto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Generini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liotta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Messerini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>F.</given-names></name></person-group><article-title>Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver</article-title><source>Intern Emerg Med</source><volume>16</volume><issue>6</issue><year>2021</year><fpage>1719</fpage><lpage>1722</lpage><pub-id pub-id-type="pmid">33550534</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s11739-021-02652-9</pub-id></element-citation></ref><ref id="b0665"><label>133</label><mixed-citation id="h0665" publication-type="other">Verma SK, Huang J, Hutchinson HG, Estevez I, Kuang K, Reynolds SL, et al. Statin use and severe acute liver injury among patients with elevated alanine aminotransferase. Clin Epidemiol. 2022 2022/1/1;14:1535-45.<pub-id assigning-authority="pmc" pub-id-type="doi">10.2147/CLEP.S385712</pub-id><pub-id pub-id-type="pmcid">PMC9759991</pub-id><pub-id pub-id-type="pmid">36540900</pub-id></mixed-citation></ref><ref id="b0670"><label>134</label><element-citation id="h0670" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Hoofnagle</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Barnhart</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kleiner</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network</article-title><source>Hepatology</source><volume>60</volume><issue>2</issue><year>2014</year><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">24700436</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.27157</pub-id><pub-id pub-id-type="pmcid">PMC4110177</pub-id></element-citation></ref><ref id="b0675"><label>135</label><element-citation id="h0675" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Perng</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.C.</given-names></name></person-group><article-title>Statin-induced liver injury in an area endemic for hepatitis b virus infection: risk factors and outcome analysis</article-title><source>Br J Clin Pharmacol</source><volume>82</volume><issue>3</issue><year>2016</year><fpage>823</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">27197051</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/bcp.13009</pub-id><pub-id pub-id-type="pmcid">PMC5338125</pub-id></element-citation></ref><ref id="b0680"><label>136</label><element-citation id="h0680" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke</article-title><source>Eur J Clin Pharmacol</source><volume>79</volume><issue>3</issue><year>2023</year><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">36580143</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00228-022-03442-8</pub-id><pub-id pub-id-type="pmcid">PMC9941271</pub-id></element-citation></ref><ref id="b0685"><label>137</label><element-citation id="h0685" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name></person-group><article-title>Rosuvastatin alleviated the liver ischemia reperfusion injury by activating the expression of peroxisome proliferator-activated receptor gamma (ppargamma)</article-title><source>J Bioenerg Biomembr</source><volume>53</volume><issue>5</issue><year>2021</year><fpage>573</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">34235609</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10863-021-09909-0</pub-id></element-citation></ref><ref id="b0690"><label>138</label><element-citation id="h0690" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Concepcion-Zavaleta</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Armas</surname><given-names>F.C.</given-names></name></person-group><article-title>Statins in liver cirrhosis in a developing country: benefits overweigh the risk?</article-title><source>Expert Opin Drug Saf</source><volume>19</volume><issue>12</issue><year>2020</year><fpage>1651</fpage><lpage>2162</lpage><pub-id pub-id-type="pmid">33047634</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/14740338.2020.1836153</pub-id></element-citation></ref><ref id="b0695"><label>139</label><element-citation id="h0695" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gracia-Sancho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abraldes</surname><given-names>J.G.</given-names></name></person-group><article-title>Cirrhosis as new indication for statins</article-title><source>Gut</source><volume>69</volume><issue>5</issue><year>2020</year><fpage>953</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">32139553</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/gutjnl-2019-318237</pub-id></element-citation></ref><ref id="b0700"><label>140</label><mixed-citation id="h0700" publication-type="other">Pagano D, Bosch J, Tuzzolino F, Oliva E, Ekser B, Zito G, et al. Donor simvastatin treatment is safe and might improve outcomes after liver transplantation: a randomized clinical trial. Transplantation. 2022 2022 Dec 1;106(12):2379-90.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/TP.0000000000004220</pub-id><pub-id pub-id-type="pmcid">PMC9698118</pub-id><pub-id pub-id-type="pmid">35862782</pub-id></mixed-citation></ref><ref id="b0705"><label>141</label><element-citation id="h0705" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gatlin</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lennon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Seonarain</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Makusky</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin</article-title><source>Toxicol Lett</source><volume>120</volume><issue>1–3</issue><year>2001</year><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">11323196</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0378-4274(01)00268-5</pub-id></element-citation></ref><ref id="b0710"><label>142</label><element-citation id="h0710" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hareedy</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>M.F.</given-names></name></person-group><article-title>Montelukast modifies simvastatin-induced myopathy and hepatotoxicity</article-title><source>Drug Dev Res</source><volume>80</volume><issue>7</issue><year>2019</year><fpage>1000</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">31389048</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/ddr.21581</pub-id></element-citation></ref><ref id="b0715"><label>143</label><element-citation id="h0715" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.Y.</given-names></name></person-group><article-title>Impact of abcc2, abcg2 and slco1b1 polymorphisms on the pharmacokinetics of pitavastatin in humans</article-title><source>Drug Metab Pharmacokinet</source><year>2013</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.2133/dmpk.dmpk-12-rg-068</pub-id><pub-id pub-id-type="pmid">23007012</pub-id></element-citation></ref><ref id="b0720"><label>144</label><element-citation id="h0720" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukunaga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mushiroda</surname><given-names>T.</given-names></name></person-group><article-title>Abcb1 polymorphism is associated with atorvastatin-induced liver injury in japanese population</article-title><source>Bmc Genet</source><year>2016</year><comment>2016 Jun 13;17(1):79</comment><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s12863-016-0390-5</pub-id><pub-id pub-id-type="pmcid">PMC4906899</pub-id><pub-id pub-id-type="pmid">27296832</pub-id></element-citation></ref><ref id="b0725"><label>145</label><element-citation id="h0725" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrag</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hamzawy</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>El-Yamany</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nassar</surname><given-names>N.N.</given-names></name></person-group><article-title>Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme q10 and/or vitamin e in hyperlipidemic rats</article-title><source>Life Sci</source><volume>15</volume><issue>203</issue><year>2018</year><fpage>129</fpage><lpage>140</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.lfs.2018.04.034</pub-id><pub-id pub-id-type="pmid">29694831</pub-id></element-citation></ref><ref id="b0730"><label>146</label><element-citation id="h0730" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meurer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.M.</given-names></name></person-group><article-title>Drug-induced liver injury from statins</article-title><source>Clin Liver Dis</source><volume>24</volume><issue>1</issue><year>2020</year><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">31753243</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cld.2019.09.007</pub-id></element-citation></ref><ref id="b0735"><label>147</label><element-citation id="h0735" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjornsson</surname><given-names>E.S.</given-names></name></person-group><article-title>Clinical management of patients with drug-induced liver injury (dili). United European</article-title><source>Gastroenterol J</source><volume>9</volume><issue>7</issue><year>2021</year><fpage>781</fpage><lpage>876</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/ueg2.12113</pub-id><pub-id pub-id-type="pmcid">PMC8435256</pub-id><pub-id pub-id-type="pmid">35084797</pub-id></element-citation></ref><ref id="b0740"><label>148</label><mixed-citation id="h0740" publication-type="other">Zhou Z, Ryan J, Ernst ME, Zoungas S, Tonkin AM, Woods RL, et al. Effect of statin therapy on cognitive decline and incident dementia in older adults. J Am Coll Cardiol. 2021 2021 Jun 29;77(25):3145-56.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0735-1097(21)04500-9</pub-id><pub-id pub-id-type="pmcid">PMC8091356</pub-id><pub-id pub-id-type="pmid">34167639</pub-id></mixed-citation></ref><ref id="b0745"><label>149</label><element-citation id="h0745" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yandrapalli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guber</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rochlani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pemmasani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jasti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Statins and the potential for higher diabetes mellitus risk</article-title><source>Expert Rev Clin Pharmacol</source><volume>12</volume><issue>9</issue><year>2019</year><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">31474169</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/17512433.2019.1659133</pub-id></element-citation></ref><ref id="b0750"><label>150</label><element-citation id="h0750" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ridker</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Danielson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Genest</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gotto</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kastelein</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein</article-title><source>N Engl J Med</source><volume>359</volume><issue>21</issue><year>2008</year><fpage>2195</fpage><lpage>2207</lpage><pub-id pub-id-type="pmid">18997196</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa0807646</pub-id></element-citation></ref><ref id="b0755"><label>151</label><element-citation id="h0755" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tobert</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Page</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>L.B.</given-names></name><etal/></person-group><article-title>Statin safety and associated adverse events: a scientific statement from the american heart association</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>39</volume><issue>2</issue><year>2019</year><fpage>e38</fpage><lpage>e81</lpage><pub-id pub-id-type="pmid">30580575</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/ATV.0000000000000073</pub-id></element-citation></ref><ref id="b0760"><label>152</label><mixed-citation id="h0760" publication-type="other">Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. Hmg-coenzyme a reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015 2015 Jan 24;385(9965):351-61.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(14)61183-1</pub-id><pub-id pub-id-type="pmcid">PMC4322187</pub-id><pub-id pub-id-type="pmid">25262344</pub-id></mixed-citation></ref><ref id="b0765"><label>153</label><mixed-citation id="h0765" publication-type="other">Hong SJ, Lee YJ, Kang WC, Hong BK, Lee JY, Lee JB, et al. Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the lodestar randomized clinical trial. Cardiovasc Diabetol. 2024 2024 Aug 7;23(1):287.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s12933-024-02386-w</pub-id><pub-id pub-id-type="pmcid">PMC11304915</pub-id><pub-id pub-id-type="pmid">39113067</pub-id></mixed-citation></ref><ref id="b0770"><label>154</label><element-citation id="h0770" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>C.</given-names></name><name name-style="western"><surname>Whisler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schnitzler</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lentine</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Incidence of statin-associated adverse events in kidney transplant recipients</article-title><source>Clin J Am Soc Nephrol</source><volume>18</volume><issue>5</issue><year>2023</year><fpage>626</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">36800538</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.2215/CJN.0000000000000124</pub-id><pub-id pub-id-type="pmcid">PMC10278779</pub-id></element-citation></ref><ref id="b0775"><label>155</label><element-citation id="h0775" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thakker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pagada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jamdade</surname><given-names>V.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name></person-group><article-title>Statin use and the risk of developing diabetes: a network meta-analysis</article-title><source>Pharmacoepidemiol Drug Saf</source><volume>25</volume><issue>10</issue><year>2016</year><fpage>1131</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">27277934</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/pds.4020</pub-id></element-citation></ref><ref id="b0780"><label>156</label><element-citation id="h0780" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cederberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stancakova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yaluri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Modi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuusisto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Laakso</surname><given-names>M.</given-names></name></person-group><article-title>Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the metsim cohort</article-title><source>Diabetologia</source><volume>58</volume><issue>5</issue><year>2015</year><fpage>1109</fpage><lpage>1117</lpage><pub-id pub-id-type="pmid">25754552</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00125-015-3528-5</pub-id></element-citation></ref><ref id="b0785"><label>157</label><mixed-citation id="h0785" publication-type="other">Curry L, Almukhtar H, Alahmed J, Roberts R, Smith PA. Simvastatin inhibits l-type ca2+-channel activity through impairment of mitochondrial function. Toxicol Sci. 2019 2019 Jun 1;169(2):543-52.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/toxsci/kfz068</pub-id><pub-id pub-id-type="pmid">30859212</pub-id></mixed-citation></ref><ref id="b0790"><label>158</label><element-citation id="h0790" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramracheya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bengtsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Karanauskaite</surname><given-names>J.</given-names></name><name name-style="western"><surname>Partridge</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion</article-title><source>Diabetes</source><volume>57</volume><issue>6</issue><year>2008</year><fpage>1618</fpage><lpage>1628</lpage><pub-id pub-id-type="pmid">18390794</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.2337/db07-0991</pub-id></element-citation></ref><ref id="b0795"><label>159</label><element-citation id="h0795" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betteridge</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Carmena</surname><given-names>R.</given-names></name></person-group><article-title>The diabetogenic action of statins - mechanisms and clinical implications</article-title><source>Nat Rev Endocrinol</source><volume>12</volume><issue>2</issue><year>2016</year><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">26668119</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/nrendo.2015.194</pub-id></element-citation></ref><ref id="b0800"><label>160</label><element-citation id="h0800" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriksbo</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Schertzer</surname><given-names>J.D.</given-names></name></person-group><article-title>Is immunity a mechanism contributing to statin-induced diabetes?</article-title><source>Adipocyte</source><year>2015</year><comment>2015 Oct-Dec;4(4):232–38</comment><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/21623945.2015.1024394</pub-id><pub-id pub-id-type="pmcid">PMC4573193</pub-id><pub-id pub-id-type="pmid">26451278</pub-id></element-citation></ref><ref id="b0805"><label>161</label><mixed-citation id="h0805" publication-type="other">Hmg-coenzyme a reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet. 2015;385(9965):351-61.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(14)61183-1</pub-id><pub-id pub-id-type="pmcid">PMC4322187</pub-id><pub-id pub-id-type="pmid">25262344</pub-id></mixed-citation></ref><ref id="b0810"><label>162</label><element-citation id="h0810" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stancakova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuulasmaa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Paananen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Bonnycastle</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>F.S.</given-names></name><etal/></person-group><article-title>Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic finnish men</article-title><source>Diabetes</source><volume>58</volume><issue>9</issue><year>2009</year><fpage>2129</fpage><pub-id pub-id-type="pmid">19502414</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.2337/db09-0117</pub-id><pub-id pub-id-type="pmcid">PMC2731523</pub-id></element-citation></ref><ref id="b0815"><label>163</label><element-citation id="h0815" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.K.W.</given-names></name><name name-style="western"><surname>Fok</surname><given-names>B.S.P.</given-names></name><name name-style="western"><surname>Wo</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C.S.</given-names></name><etal/></person-group><article-title>Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits abcg2-mediated transport of rosuvastatin</article-title><source>Eur J Clin Pharmacol</source><volume>72</volume><issue>12</issue><year>2016</year><fpage>1</fpage><lpage>08</lpage><pub-id pub-id-type="pmid">27651239</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00228-016-2130-1</pub-id></element-citation></ref><ref id="b0820"><label>164</label><mixed-citation id="h0820" publication-type="other">Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian randomization study of pcsk9 and hmg-coa reductase inhibition and cognitive function. J Am Coll Cardiol. 2022 2022 Aug 16;80(7):653-62.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jacc.2022.05.041</pub-id><pub-id pub-id-type="pmid">35953131</pub-id></mixed-citation></ref><ref id="b0825"><label>165</label><mixed-citation id="h0825" publication-type="other">Heart PSCG. Effects on 11-year mortality and morbidity of lowering ldl cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011 2011 Dec 10;378(9808):2013-20.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(11)61125-2</pub-id><pub-id pub-id-type="pmcid">PMC3242163</pub-id><pub-id pub-id-type="pmid">22115874</pub-id></mixed-citation></ref><ref id="b0830"><label>166</label><element-citation id="h0830" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagstaff</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Mitton</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Arvik</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Doraiswamy</surname><given-names>P.M.</given-names></name></person-group><article-title>Statin-associated memory loss: analysis of 60 case reports and review of the literature</article-title><source>Pharmacotherapy</source><volume>23</volume><issue>7</issue><year>2003</year><fpage>871</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">12885101</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1592/phco.23.7.871.32720</pub-id></element-citation></ref><ref id="b0835"><label>167</label><element-citation id="h0835" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Healy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chinnaswamy</surname><given-names>S.</given-names></name></person-group><article-title>Transient global amnesia associated with statin intake</article-title><source>Bmj Case Rep</source><year>2009</year><object-id pub-id-type="publisher-id">2009/1/1;2009</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/bcr.06.2008.0033</pub-id><pub-id pub-id-type="pmcid">PMC3027897</pub-id><pub-id pub-id-type="pmid">21686951</pub-id></element-citation></ref><ref id="b0840"><label>168</label><element-citation id="h0840" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.N.</given-names></name></person-group><article-title>Neuroprotective effects of statins against amyloid beta-induced neurotoxicity</article-title><source>Neural Regen Res</source><volume>13</volume><issue>2</issue><year>2018</year><fpage>198</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">29557360</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.4103/1673-5374.226379</pub-id><pub-id pub-id-type="pmcid">PMC5879882</pub-id></element-citation></ref><ref id="b0845"><label>169</label><element-citation id="h0845" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bellosta</surname><given-names>S.</given-names></name></person-group><article-title>Cholesterol: its regulation and role in central nervous system disorders</article-title><source>Cholesterol</source><volume>2012/1/1;2012</volume><year>2012</year><object-id pub-id-type="publisher-id">292598</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1155/2012/292598</pub-id><pub-id pub-id-type="pmcid">PMC3483652</pub-id><pub-id pub-id-type="pmid">23119149</pub-id></element-citation></ref><ref id="b0850"><label>170</label><element-citation id="h0850" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vega</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Lipton</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Von Bergmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lutjohann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Reduction in levels of 24s-hydroxycholesterol by statin treatment in patients with alzheimer disease</article-title><source>Arch Neurol</source><volume>60</volume><issue>4</issue><year>2003</year><fpage>510</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">12707064</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/archneur.60.4.510</pub-id></element-citation></ref><ref id="b0855"><label>171</label><element-citation id="h0855" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thelen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Laaksonen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lehtimaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lutjohann</surname><given-names>D.</given-names></name></person-group><article-title>High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels</article-title><source>J Clin Pharmacol</source><volume>46</volume><issue>7</issue><year>2006</year><fpage>812</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">16809807</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/0091270006289851</pub-id></element-citation></ref><ref id="b0860"><label>172</label><element-citation id="h0860" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutjohann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stroick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bertsch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuhl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lindenthal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thelen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs</article-title><source>Steroids</source><volume>69</volume><issue>6</issue><year>2004</year><fpage>431</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">15219793</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.steroids.2004.03.012</pub-id></element-citation></ref><ref id="b0865"><label>173</label><element-citation id="h0865" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemi</surname><given-names>M.</given-names></name></person-group><article-title>Role of oatp transporters in the disposition of drugs</article-title><source>Pharmacogenomics</source><volume>8</volume><issue>7</issue><year>2007</year><fpage>787</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">18240907</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.2217/14622416.8.7.787</pub-id></element-citation></ref><ref id="b0870"><label>174</label><element-citation id="h0870" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kikuchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kusuhara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Endou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y.</given-names></name></person-group><article-title>Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors across the blood-brain barrier</article-title><source>J Pharmacol Exp Ther</source><volume>311</volume><issue>3</issue><year>2004</year><fpage>1147</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">15292460</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1124/jpet.104.071621</pub-id></element-citation></ref><ref id="b0875"><label>175</label><mixed-citation id="h0875" publication-type="other">Amarenco P, Bogousslavsky J, Callahan AR, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 2006 Aug 10;355(6):549-59.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa061894</pub-id><pub-id pub-id-type="pmid">16899775</pub-id></mixed-citation></ref><ref id="b0880"><label>176</label><element-citation id="h0880" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betrisey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haller</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Efthimiou</surname><given-names>O.</given-names></name><name name-style="western"><surname>Speierer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Del</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Moutzouri</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials</article-title><source>J Am Heart Assoc</source><year>2024</year><comment>2024 Feb 20;13(4):e30714</comment><pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/JAHA.123.030714</pub-id><pub-id pub-id-type="pmcid">PMC11010101</pub-id><pub-id pub-id-type="pmid">38323514</pub-id></element-citation></ref><ref id="b0885"><label>177</label><mixed-citation id="h0885" publication-type="other">Goldstein LB, Amarenco P, Szarek M, Callahan AR, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008 2008 Jun 10;70(24 Pt 2):2364-70.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1212/01.wnl.0000296277.63350.77</pub-id><pub-id pub-id-type="pmid">18077795</pub-id></mixed-citation></ref><ref id="b0890"><label>178</label><element-citation id="h0890" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sobonya</surname><given-names>R.</given-names></name></person-group><article-title>Statins as a potential risk factor for autoimmune diseases</article-title><source>Am J Ther</source><volume>1</volume><year>2013</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MJT.0b013e31828e5bfb</pub-id><pub-id pub-id-type="pmid">23782756</pub-id></element-citation></ref><ref id="b0895"><label>179</label><element-citation id="h0895" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>C.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>Statins and the risk of gastric cancer: a systematic review and meta-analysis</article-title><source>J Clin Med</source><volume>11</volume><issue>23</issue><year>2022</year><fpage>7180</fpage><pub-id pub-id-type="pmid">36498753</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/jcm11237180</pub-id><pub-id pub-id-type="pmcid">PMC9739712</pub-id></element-citation></ref><ref id="b0900"><label>180</label><element-citation id="h0900" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Statins are associated with improved survival of patients with gastric cancer: a systematic review and meta-analysis</article-title><source>Int J Clin Pract</source><volume>2022</volume><year>2022</year><fpage>1</fpage><lpage>09</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1155/2022/4938539</pub-id><pub-id pub-id-type="pmcid">PMC9158792</pub-id><pub-id pub-id-type="pmid">35685487</pub-id></element-citation></ref><ref id="b0905"><label>181</label><element-citation id="h0905" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>E.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hendifar</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Mita</surname><given-names>M.M.</given-names></name></person-group><article-title>Statins and pancreatic cancer</article-title><source>Oncol Lett</source><year>2017</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.3892/ol.2017.5572</pub-id><pub-id pub-id-type="pmcid">PMC5403279</pub-id><pub-id pub-id-type="pmid">28454210</pub-id></element-citation></ref><ref id="b0910"><label>182</label><element-citation id="h0910" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ruscica</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Corsini</surname><given-names>A.</given-names></name></person-group><article-title>Fixed combination for the treatment of dyslipidaemia</article-title><source>Curr Atheroscler Rep</source><volume>25</volume><issue>10</issue><year>2023</year><fpage>691</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">37715044</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s11883-023-01142-x</pub-id><pub-id pub-id-type="pmcid">PMC10564832</pub-id></element-citation></ref><ref id="b0915"><label>183</label><element-citation id="h0915" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Mamdani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>D.A.</given-names></name></person-group><article-title>Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox</article-title><source>JAMA</source><volume>291</volume><issue>15</issue><year>2004</year><fpage>1864</fpage><lpage>1870</lpage><pub-id pub-id-type="pmid">15100205</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1001/jama.291.15.1864</pub-id></element-citation></ref></ref-list><bio><graphic id="lk00070" orientation="portrait" position="float" xlink:href="fx1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><p><bold>Weiwei Zeng,</bold> is a high-caliber personnel of Shenzhen, elite personnel of Shenzhen Health Commission. she is is the director of the Department of Pharmacy at Shenzhen Longgang Second People's Hospital,518112,Shenzhen, Guangdong, China. She is the pharmacology master's supervisor in Shantou University, and the supervisor of the off-campus joint training of clinical pharmacy in the School of Pharmacy of Sun Yat-sen University. She focuses on epigenetic pharmacology, pharmacogenomics, and individualized medicine research of hypertension/hyperlipidemia/ hyperglycemia/ breast cancer and other diseases. she has published 25 articles as the first author or corresponding author. Email:zwwspring@126.com.</p></bio><bio><graphic id="lk00075" orientation="portrait" position="float" xlink:href="fx2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><p><bold>Huan Deng</bold>, graduated from Shenzhen University School of Medicine with a master's degree, is engaged in pharmacology research with a focus on ulcerative colitis. he is working in Shenzhen Longgang Second People's Hospital, 518112, Shenzhen, Guangdong, China. He focuses on adverse drug reactions in cardiovascular disease. He has published 2 SCI paper as co-first author. Email:2070245030@email.szu.edu.cn.</p></bio><bio><graphic id="lk00080" orientation="portrait" position="float" xlink:href="fx3.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><p><bold>Yuning Luo</bold>, graduated from University of South China with a master's degree, and was engaged in the research of antitumor drugs with nanomedicine carriers. Currently, she is working in Shenzhen Longgang Second People's Hospital, 518112, Shenzhen, Guangdong, China. she is engaging in the study of adverse drug reactions in cardiovascular diseases such as diabetes mellitus, hypertension, hyperlipidemia and other cardiovascular diseases. she has published 4 SCI papers as first author or co-first author. Email:Luo1748058392@163.com.</p></bio><bio><graphic id="lk00085" orientation="portrait" position="float" xlink:href="fx4.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><p><bold>Shilong Zhong,</bold> M.S. and Ph.D supervisor, is currently the director of the Department of Pharmacy at Guangdong Provincial People's Hospital.510000, Guangzhou, Guangdong, China. he focuses on clinical pharmacology and clinical pharmacology of cardiovascular diseases, multi-omics research, pharmacokinetics, and drug metabolism. He is the head of more than 10 provincial and national projects and applied for 15 invention patents,. He has published more than 50 SCI papers as corresponding author or first author, including Clin Transl Med, Nat Commun, Clin Pharmacol Ther etc. Email:shz2020@qq.com.</p></bio><bio><graphic id="lk00090" orientation="portrait" position="float" xlink:href="fx5.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><p><bold>Min Huang,</bold> is a doctoral supervisor. He is the director of the Clinical Pharmacology Research Institute at Sun Yat-sen University, 510000, Guangzhou,Guangdong, China. He has served as committee member of various pharmceutical societies,such as Chinese Pharmacopoeia Commission and the Steering Committee of Postgraduate Education in Pharmacy of China et al. Huang’s reserch focus on clinical pharmacology and pharmacokinetics, personalized medicine and pharmacotherapy, and intestinal microbiome of anti-cardiovascular, anticoagulant, anti-epileptic and anti-tumor drugs.he has been award almost 30grants from Chinese government. He has published more than 300 papers(&gt;250 SCI papers). Email:huangmin@mail.sysu.edu.cn.</p></bio><bio><graphic id="lk00095" orientation="portrait" position="float" xlink:href="fx6.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><p><bold>BrianTomlinson</bold> , a doctoral supervisor, is a professor in the Faculty of Medicine at Macau University of Science and Technology (MUST), Macau, 999078, China. He specializes in lipid disorders, genetics of metabolic diseases, and diabetes, hypertension, hyperlipidemia and other cardiovascular diseases. He has been awarded numerous grants for research and has been an investigator in many clinical trials. He has published extensively in major journals, including The New England Journal of Medicine, The Lancet and Nature, with H Index 59 and 580 publications. Email:btomlinson@must.edu.mo.</p></bio><ack id="ak005"><title>Acknowledgments</title><p id="p0255">This work was supported by Project of Guangdong Provincial Key Laboratory of New Drug Design and Evaluation (No. 2020B1212060034).</p></ack></back></article>